<?xml version='1.0' encoding='UTF-8'?>
<chapter id="ch0155">
    <title>133 Antifungal Agents</title>
    <sect1 id="ch0155s0001">
      <title>133 Antifungal Agents</title>
      <anchor id="ch0155s0001a0001"/>
      <anchor id="ch0155s0001a0002"/>
      <para id="ch0155s0001p0001" role="chapterAuthor">SHAWN R. LOCKHART AND ELIZABETH L. BERKOW</para>
      <para id="ch0155s0001p0002">After a long period of slow development, we have recently seen the expansion through chemical modification of two classes of antifungal agents (the echinocandins and the triazoles) and the development of novel methods for delivering established agents (itraconazole and amphotericin B). These developments will change the standards of care for the treatment of many invasive fungal infections, particularly aspergillosis and candidiasis. The comparative activities of the major systemic antifungal agents against important groups of fungi are summarized in<anchor id="ch0155s0001a0003"/><link linkend="ch0155s0003s0004a0003">Table 1</link>. This chapter will also discuss the characteristics of the several other agents that can be used for the oral or parenteral treatment of superficial, subcutaneous, or systemic fungal infections. Novel agents that are currently in or have finished phase II clinical trials are also reviewed.</para>
      <sect2 id="ch0155s0001s0001">
        <title>ALLYLAMINES</title>
        <anchor id="ch0155s0001s0001a0001"/>
        <anchor id="ch0155s0001s0001a0002"/>
        <para id="ch0155s0001s0001p0001">The allylamines are a group of synthetic antifungal compounds effective in the topical and oral treatment of dermatophytoses. Two drugs, terbinafine and naftifine, are licensed for clinical use. Naftifine is only available as a topical preparation.</para>
      </sect2>
    </sect1>
    <sect1 id="ch0155s0002">
      <title>Mechanism of Action</title>
      <anchor id="ch0155s0002a0001"/>
      <anchor id="ch0155s0002a0002"/>
      <para id="ch0155s0002p0001">The allylamines inhibit squalene epoxidase, a critical enzyme in the formation of ergosterol, the principal sterol in the membrane of susceptible fungal cells. The consequent accumulation of squalene leads to membrane disruption and cell death (<link linkend="ch0155s0033s0002li0001">1</link>).</para>
    </sect1>
    <sect1 id="ch0155s0003">
      <title>Terbinafine</title>
      <anchor id="ch0155s0003a0001"/>
      <anchor id="ch0155s0003a0002"/>
      <para id="ch0155s0003p0001">Terbinafine (Lamisil, Novartis Pharmaceuticals) is a lipophilic drug that is available for oral or topical administration. It is widely used for the treatment of superficial fungal infections of skin, hair, and nails caused by dermatophytes.</para>
      <sect2 id="ch0155s0003s0001">
        <title>Spectrum of Activity</title>
        <anchor id="ch0155s0003s0001a0001"/>
        <anchor id="ch0155s0003s0001a0002"/>
        <para id="ch0155s0003s0001p0001">Terbinafine is effective against several groups of pathogenic fungi, including dermatophytes (e.g.,<emphasis>Epidermophyton, Microsporum, Nannizzia</emphasis>, and <emphasis>Trichophyton</emphasis>) (<link linkend="ch0155s0033s0002li0002">2</link>–<link linkend="ch0155s0033s0002li0004">4</link>) and dematiaceous fungi (<link linkend="ch0155s0033s0002li0005">5</link>). It also has some activity against <emphasis>Aspergillus</emphasis> spp. (<link linkend="ch0155s0033s0002li0006">6</link>), <emphasis>Candida</emphasis> spp. (<link linkend="ch0155s0033s0002li0007">7</link>), <emphasis>Blastomyces dermatitidis</emphasis> and <emphasis>Histoplasma capsulatum</emphasis> (<link linkend="ch0155s0033s0002li0008">8</link>), <emphasis>Paracoccidioides brasiliensis</emphasis> (<link linkend="ch0155s0033s0002li0009">9</link>), <emphasis>Talaromyces marneffei</emphasis> (<link linkend="ch0155s0033s0002li0010">10</link>), and <emphasis>Sporothrix schenckii</emphasis> (<link linkend="ch0155s0033s0002li0008">8</link>).</para>
      </sect2>
      <sect2 id="ch0155s0003s0002">
        <title>Acquired Resistance</title>
        <anchor id="ch0155s0003s0002a0001"/>
        <anchor id="ch0155s0003s0002a0002"/>
        <para id="ch0155s0003s0002p0001">The development of resistance to terbinafine among dermatophytes is an emerging global threat (<link linkend="ch0155s0033s0002li0011">11</link>, <link linkend="ch0155s0033s0002li0012">12</link>). This threat is specifically among isolates of a new species called <emphasis>Trichophyton indotineae</emphasis>, but resistance has recently become more common among other species of dermatophytes as well (<link linkend="ch0155s0033s0002li0011">11</link>, <link linkend="ch0155s0033s0002li0013">13</link>–<link linkend="ch0155s0033s0002li0015">15</link>). There is evidence that one or more clones of <emphasis>T. indotineae</emphasis> that contain specific mutations in the squalene epoxidase gene (Phe397Leu and Leu393Ser) have emerged from the Indian subcontinent and are spreading throughout the world (<link linkend="ch0155s0033s0002li0016">16</link>–<link linkend="ch0155s0033s0002li0018">18</link>).</para>
      </sect2>
      <sect2 id="ch0155s0003s0003">
        <title>Pharmacokinetics</title>
        <anchor id="ch0155s0003s0003a0001"/>
        <anchor id="ch0155s0003s0003a0002"/>
        <para id="ch0155s0003s0003p0001">Terbinafine is well absorbed after oral administration and is then rapidly and extensively distributed to body tissues (<link linkend="ch0155s0033s0002li0019">19</link>). It reaches the stratum corneum as a result of diffusion through the dermis and epidermis and secretion in sebum. Diffusion from the nail bed is the major factor in its rapid penetration of nails. Terbinafine has been found to persist in nail for long periods after cessation of treatment. It is extensively metabolized by the human hepatic cytochrome P-450 enzyme system, and the inactive metabolites are mostly excreted in the urine (<link linkend="ch0155s0033s0002li0020">20</link>).</para>
      </sect2>
      <sect2 id="ch0155s0003s0004">
        <title>Clinical Use</title>
        <anchor id="ch0155s0003s0004a0001"/>
        <anchor id="ch0155s0003s0004a0002"/>
        <para id="ch0155s0003s0004p0001">Oral terbinafine is the drug of choice for dermatophyte infections of the skin, hair, and nails where topical treatment is considered inappropriate or has failed (<link linkend="ch0155s0033s0002li0021">21</link>, <link linkend="ch0155s0033s0002li0022">22</link>). It is not as effective as itraconazole for treatment of fungal nail infections (onychomycosis) involving non-dermatophytes, and it may not be as effective in scalp infections with <emphasis>Microsporum canis.</emphasis> Terbinafine has also proven effective in some patients with aspergillosis, chromoblastomycosis, and sporotrichosis (<link linkend="ch0155s0033s0002li0023">23</link>), but it is not licensed for these indications. Anecdotal evidence suggests that the use of terbinafine in combination with voriconazole may be beneficial in the treatment of infections with <emphasis>Lomentospora prolificans</emphasis> (<link linkend="ch0155s0033s0002li0024">24</link>, <link linkend="ch0155s0033s0002li0025">25</link>). Neither the Clinical and Laboratory Standards Institute (CLSI) nor the European Committee on Antimicrobial Susceptibility Testing (EUCAST) has established breakpoints for terbinafine against any species of fungus.</para>
        <table id="ch0155s0003s0004t0001"><title><emphasis role="strong"><phrase role="figureLabel"><anchor id="ch0155s0003s0004a0003"/><link linkend="ch0155s0001a0003">TABLE 1</link></phrase></emphasis> Spectrum and extent of activity of commonly used systemic antifungal agents<superscript><emphasis><anchor id="ch0155s0003s0004a0004"/><link linkend="ch0155s0003s0004a0006">a</link></emphasis></superscript>
</title>
          
          <tgroup cols="10">
            <tbody>
              <row>
                <entry><phrase role="center">Organism</phrase>
                </entry>
                <entry><phrase role="center">Activity<superscript><emphasis><anchor id="ch0155s0003s0004a0005"/><link linkend="ch0155s0003s0004a0007">b</link></emphasis></superscript> of antifungal agent</phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="center">Amphotericin</phrase>
                </entry>
                <entry><phrase role="center">Fluconazole</phrase>
                </entry>
                <entry><phrase role="center">Isavuconazole</phrase>
                </entry>
                <entry><phrase role="center">Itraconazole</phrase>
                </entry>
                <entry><phrase role="center">Posaconazole</phrase>
                </entry>
                <entry><phrase role="center">Voriconazole</phrase>
                </entry>
                <entry><phrase role="center">Anidulafungin</phrase>
                </entry>
                <entry><phrase role="center">Caspofungin</phrase>
                </entry>
                <entry><phrase role="center">Micafungin</phrase>
                </entry>
              </row>
              <row>
                <entry><emphasis>Aspergillus</emphasis> spp.</entry>
                <entry><phrase role="center">+++</phrase>
                </entry>
                <entry><phrase role="center">–</phrase>
                </entry>
                <entry><phrase role="center">+++</phrase>
                </entry>
                <entry><phrase role="center">++</phrase>
                </entry>
                <entry><phrase role="center">+++</phrase>
                </entry>
                <entry><phrase role="center">+++</phrase>
                </entry>
                <entry><phrase role="center">++</phrase>
                </entry>
                <entry><phrase role="center">++</phrase>
                </entry>
                <entry><phrase role="center">++</phrase>
                </entry>
              </row>
              <row>
                <entry><emphasis>B. dermatitidis</emphasis>
                </entry>
                <entry><phrase role="center">+++</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">+++</phrase>
                </entry>
                <entry><phrase role="center">+++</phrase>
                </entry>
                <entry><phrase role="center">+++</phrase>
                </entry>
                <entry><phrase role="center">+++</phrase>
                </entry>
                <entry><phrase role="center">–</phrase>
                </entry>
                <entry><phrase role="center">–</phrase>
                </entry>
                <entry><phrase role="center">–</phrase>
                </entry>
              </row>
              <row>
                <entry><emphasis>Candida</emphasis> spp.</entry>
                <entry/>
              </row>
              <row>
                <entry><emphasis>C. albicans</emphasis>
                </entry>
                <entry><phrase role="center">+++</phrase>
                </entry>
                <entry><phrase role="center">+++</phrase>
                </entry>
                <entry><phrase role="center">+++</phrase>
                </entry>
                <entry><phrase role="center">+++</phrase>
                </entry>
                <entry><phrase role="center">+++</phrase>
                </entry>
                <entry><phrase role="center">+++</phrase>
                </entry>
                <entry><phrase role="center">+++</phrase>
                </entry>
                <entry><phrase role="center">+++</phrase>
                </entry>
                <entry><phrase role="center">+++</phrase>
                </entry>
              </row>
              <row>
                <entry><emphasis>C. glabrata</emphasis>
                </entry>
                <entry><phrase role="center">+++</phrase>
                </entry>
                <entry><phrase role="center">++</phrase>
                </entry>
                <entry><phrase role="center">++</phrase>
                </entry>
                <entry><phrase role="center">++</phrase>
                </entry>
                <entry><phrase role="center">++</phrase>
                </entry>
                <entry><phrase role="center">++</phrase>
                </entry>
                <entry><phrase role="center">+++</phrase>
                </entry>
                <entry><phrase role="center">+++</phrase>
                </entry>
                <entry><phrase role="center">+++</phrase>
                </entry>
              </row>
              <row>
                <entry><emphasis>C. krusei</emphasis>
                </entry>
                <entry><phrase role="center">++</phrase>
                </entry>
                <entry><phrase role="center">–</phrase>
                </entry>
                <entry><phrase role="center">+++</phrase>
                </entry>
                <entry><phrase role="center">+++</phrase>
                </entry>
                <entry><phrase role="center">+++</phrase>
                </entry>
                <entry><phrase role="center">+++</phrase>
                </entry>
                <entry><phrase role="center">+++</phrase>
                </entry>
                <entry><phrase role="center">+++</phrase>
                </entry>
                <entry><phrase role="center">+++</phrase>
                </entry>
              </row>
              <row>
                <entry><emphasis>C. lusitaniae</emphasis>
                </entry>
                <entry><phrase role="center">++</phrase>
                </entry>
                <entry><phrase role="center">+++</phrase>
                </entry>
                <entry><phrase role="center">+++</phrase>
                </entry>
                <entry><phrase role="center">+++</phrase>
                </entry>
                <entry><phrase role="center">+++</phrase>
                </entry>
                <entry><phrase role="center">+++</phrase>
                </entry>
                <entry><phrase role="center">++</phrase>
                </entry>
                <entry><phrase role="center">++</phrase>
                </entry>
                <entry><phrase role="center">++</phrase>
                </entry>
              </row>
              <row>
                <entry><emphasis>C. parapsilosis</emphasis>
                </entry>
                <entry><phrase role="center">+++</phrase>
                </entry>
                <entry><phrase role="center">+++</phrase>
                </entry>
                <entry><phrase role="center">+++</phrase>
                </entry>
                <entry><phrase role="center">+++</phrase>
                </entry>
                <entry><phrase role="center">+++</phrase>
                </entry>
                <entry><phrase role="center">+++</phrase>
                </entry>
                <entry><phrase role="center">++</phrase>
                </entry>
                <entry><phrase role="center">++</phrase>
                </entry>
                <entry><phrase role="center">++</phrase>
                </entry>
              </row>
              <row>
                <entry><emphasis>C. tropicalis</emphasis>
                </entry>
                <entry><phrase role="center">+++</phrase>
                </entry>
                <entry><phrase role="center">+++</phrase>
                </entry>
                <entry><phrase role="center">+++</phrase>
                </entry>
                <entry><phrase role="center">+++</phrase>
                </entry>
                <entry><phrase role="center">+++</phrase>
                </entry>
                <entry><phrase role="center">+++</phrase>
                </entry>
                <entry><phrase role="center">+++</phrase>
                </entry>
                <entry><phrase role="center">+++</phrase>
                </entry>
                <entry><phrase role="center">+++</phrase>
                </entry>
              </row>
              <row>
                <entry><emphasis>Coccidioides</emphasis> spp.</entry>
                <entry><phrase role="center">+++</phrase>
                </entry>
                <entry><phrase role="center">+++</phrase>
                </entry>
                <entry><phrase role="center">+++</phrase>
                </entry>
                <entry><phrase role="center">+++</phrase>
                </entry>
                <entry><phrase role="center">+++</phrase>
                </entry>
                <entry><phrase role="center">+++</phrase>
                </entry>
                <entry><phrase role="center">–</phrase>
                </entry>
                <entry><phrase role="center">–</phrase>
                </entry>
                <entry><phrase role="center">–</phrase>
                </entry>
              </row>
              <row>
                <entry><emphasis>Cryptococcus</emphasis> spp.</entry>
                <entry><phrase role="center">+++</phrase>
                </entry>
                <entry><phrase role="center">+++</phrase>
                </entry>
                <entry><phrase role="center">+++</phrase>
                </entry>
                <entry><phrase role="center">++</phrase>
                </entry>
                <entry><phrase role="center">+++</phrase>
                </entry>
                <entry><phrase role="center">+++</phrase>
                </entry>
                <entry><phrase role="center">–</phrase>
                </entry>
                <entry><phrase role="center">–</phrase>
                </entry>
                <entry><phrase role="center">–</phrase>
                </entry>
              </row>
              <row>
                <entry><emphasis>Fusarium</emphasis> spp.</entry>
                <entry><phrase role="center">++</phrase>
                </entry>
                <entry><phrase role="center">–</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">++</phrase>
                </entry>
                <entry><phrase role="center">++</phrase>
                </entry>
                <entry><phrase role="center">–</phrase>
                </entry>
                <entry><phrase role="center">–</phrase>
                </entry>
                <entry><phrase role="center">–</phrase>
                </entry>
              </row>
              <row>
                <entry><emphasis>H. capulatum</emphasis>
                </entry>
                <entry><phrase role="center">+++</phrase>
                </entry>
                <entry><phrase role="center">–</phrase>
                </entry>
                <entry><phrase role="center">+++</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">++</phrase>
                </entry>
                <entry><phrase role="center">++</phrase>
                </entry>
                <entry><phrase role="center">–</phrase>
                </entry>
                <entry><phrase role="center">–</phrase>
                </entry>
                <entry><phrase role="center">–</phrase>
                </entry>
              </row>
              <row>
                <entry>Mucorales</entry>
                <entry><phrase role="center">++</phrase>
                </entry>
                <entry><phrase role="center">–</phrase>
                </entry>
                <entry><phrase role="center">++</phrase>
                </entry>
                <entry><phrase role="center">–</phrase>
                </entry>
                <entry><phrase role="center">++</phrase>
                </entry>
                <entry><phrase role="center">–</phrase>
                </entry>
                <entry><phrase role="center">–</phrase>
                </entry>
                <entry><phrase role="center">–</phrase>
                </entry>
                <entry><phrase role="center">–</phrase>
                </entry>
              </row>
              <row>
                <entry><emphasis>P. brasiliensis</emphasis>
                </entry>
                <entry><phrase role="center">+++</phrase>
                </entry>
                <entry><phrase role="center">++</phrase>
                </entry>
                <entry><phrase role="center">+++</phrase>
                </entry>
                <entry><phrase role="center">+++</phrase>
                </entry>
                <entry><phrase role="center">+++</phrase>
                </entry>
                <entry><phrase role="center">+++</phrase>
                </entry>
                <entry><phrase role="center">–</phrase>
                </entry>
                <entry><phrase role="center">–</phrase>
                </entry>
                <entry><phrase role="center">–</phrase>
                </entry>
              </row>
            </tbody>
          </tgroup>
        </table>
        <para role="table-footnote"><superscript><emphasis><anchor id="ch0155s0003s0004a0006"/><link linkend="ch0155s0003s0004a0004">a</link></emphasis></superscript> This table is a general overview for comparison of the activities of some systemic drugs against various fungi. Readers are recommended to refer to the text for more detailed information.</para>
        <para role="table-footnote"><superscript><emphasis><anchor id="ch0155s0003s0004a0007"/><link linkend="ch0155s0003s0004a0005">b</link></emphasis></superscript> –, no meaningful activity; +, occasional activity; ++, moderate activity but resistance is noted; +++, reliable activity with occasional resistance.</para>
      </sect2>
      <sect2 id="ch0155s0003s0005">
        <title>Drug Interactions</title>
        <anchor id="ch0155s0003s0005a0001"/>
        <anchor id="ch0155s0003s0005a0002"/>
        <anchor id="ch0155s0003s0005a0003"/>
        <para id="ch0155s0003s0005p0001">Although terbinafine is metabolized by the human hepatic cytochrome P-450 enzyme system, it does not inhibit most CYP enzymes at clinically relevant concentrations (<link linkend="ch0155s0033s0002li0020">20</link>). Blood concentrations of terbinafine are reduced when it is given together with drugs, such as rifampin, that induce the hepatic cytochrome P-450 system.</para>
      </sect2>
      <sect2 id="ch0155s0003s0006">
        <title>Toxicity and Adverse Effects</title>
        <anchor id="ch0155s0003s0006a0001"/>
        <anchor id="ch0155s0003s0006a0002"/>
        <para id="ch0155s0003s0006p0001">Terbinafine produces few adverse reactions. These include abdominal discomfort, nausea, diarrhea, impairment of taste, and transient skin rashes (<link linkend="ch0155s0033s0002li0026">26</link>). Rare, but serious, side effects include Stevens-Johnson syndrome and hepatotoxic reactions, including cholestasis and hepatitis.</para>
      </sect2>
      <sect2 id="ch0155s0003s0007">
        <title>AZOLES</title>
        <anchor id="ch0155s0003s0007a0001"/>
        <anchor id="ch0155s0003s0007a0002"/>
        <para id="ch0155s0003s0007p0001">This large group of synthetic agents contains many compounds that are effective in the topical treatment of dermatophyte infections and superficial forms of candidiasis; a number are suitable for systemic administration. Members of this group have in common an imidazole or triazole ring with N-carbon substitution. The systemic-use antifungals are the triazoles.</para>
      </sect2>
    </sect1>
    <sect1 id="ch0155s0004">
      <title>Mechanism of Action</title>
      <anchor id="ch0155s0004a0001"/>
      <anchor id="ch0155s0004a0002"/>
      <para id="ch0155s0004p0001">Azole compounds inhibit a fungal cytochrome P-450-dependent enzyme, lanosterol 14α-demethylase, which is responsible for the conversion of lanosterol to ergosterol, the principal sterol in the membrane of susceptible fungal cells. This results in the accumulation of various toxic methylated sterols and the depletion of ergosterol, with subsequent disruption of membrane structure and function. The activity is essentially fungistatic, although voriconazole and itraconazole can exert fungicidal effects against<emphasis>Aspergillus</emphasis> and some other mold species at concentrations achieved with recommended dosages (<link linkend="ch0155s0033s0002li0027">27</link>).</para>
      <para id="ch0155s0004p0002">Several mechanisms of resistance have been described (see<ulink url="ch0156#ch0156s0001">chapter 134</ulink> of this <emphasis>Manual</emphasis>). These include upregulation of multidrug efflux transporter genes, upregulation or duplication of the <emphasis>ERG11</emphasis> gene that encodes the target enzyme, lanosterol 14α-demethylase, and decreased affinity of this enzyme for azole agents due to either intrinsic or acquired amino acid substitutions (<link linkend="ch0155s0033s0002li0028">28</link>, <link linkend="ch0155s0033s0002li0029">29</link>). Changes in other enzymes involved in the ergosterol biosynthesis pathway, such as loss of Δ<superscript>5,6</superscript> sterol desaturase activity, may also contribute to azole resistance (<link linkend="ch0155s0033s0002li0028">28</link>). When azole resistance is efflux mediated, there is often cross-resistance among all the azoles.</para>
    </sect1>
    <sect1 id="ch0155s0005">
      <title>Pharmacokinetics</title>
      <anchor id="ch0155s0005a0001"/>
      <anchor id="ch0155s0005a0002"/>
      <para id="ch0155s0005p0001">With the exception of fluconazole and isavuconazole, food has a significant effect on the absorption of azole antifungals. Administration with lipid-rich food improves the absorption of ketoconazole, posaconazole, and the capsule formulation of itraconazole (<link linkend="ch0155s0033s0002li0030">30</link>, <link linkend="ch0155s0033s0002li0031">31</link>). In contrast, absorption of voriconazole and the oral solution formulation of itraconazole is reduced when given with a high-fat meal (<link linkend="ch0155s0033s0002li0032">32</link>).</para>
      <para id="ch0155s0005p0002">Peak blood concentrations of azoles are typically reached within 2 to 3 h after oral administration. With fluconazole and posaconazole, blood levels increase in proportion to dosage (<link linkend="ch0155s0033s0002li0033">33</link>). In contrast, increases in itraconazole dosage produce disproportionate changes in peak blood concentrations due to saturable first-pass metabolism in the liver (<link linkend="ch0155s0033s0002li0034">34</link>). In adults, there is a disproportionate increase in blood levels of voriconazole with increasing oral and parenteral dosage (<link linkend="ch0155s0033s0002li0035">35</link>). In children, however, increases in dosage produce proportional changes in drug levels, and clearance of the drug is more rapid (<link linkend="ch0155s0033s0002li0036">36</link>).</para>
      <anchor id="ch0155s0005a0003"/>
      <beginpage pagenum="2621"/>
      <para id="ch0155s0005p0003">Due to its low protein binding (about 12%), fluconazole attains high concentrations in most tissues and body fluids. Levels of the drug in cerebrospinal fluid (CSF) usually exceed 50% of the simultaneous blood concentration (<link linkend="ch0155s0033s0002li0035">35</link>). Likewise, voriconazole is extensively distributed into tissues, with CSF levels that are around 30 to 60% of the simultaneous blood concentration (<link linkend="ch0155s0033s0002li0037">37</link>). Voriconazole and fluconazole concentrations in vitreous and aqueous fluids are around 40 to 50% of the simultaneous blood level, which makes them useful for treating endophthalmitis (<link linkend="ch0155s0033s0002li0038">38</link>). Levels of itraconazole in the CSF are minimal (<link linkend="ch0155s0033s0002li0030">30</link>).</para>
      <para id="ch0155s0005p0004">Levels of itraconazole in tissues, such as lung, liver, brain, and bone, are two to three times higher than in serum. High concentrations are also found in the stratum corneum as a result of drug secretion in sebum (<link linkend="ch0155s0033s0002li0039">39</link>). Itraconazole has been found to persist in the skin and nails for weeks to months after the end of a course of treatment, thereby allowing intermittent pulse regimens for dermatophyte infections and onychomycosis (<link linkend="ch0155s0033s0002li0030">30</link>, <link linkend="ch0155s0033s0002li0039">39</link>).</para>
      <para id="ch0155s0005p0005">With the exception of fluconazole and posaconazole, the azoles are extensively metabolized by the human hepatic cytochrome P-450 enzyme system and are eliminated as inactive metabolites in the bile or urine. More than 90% of a dose of fluconazole is eliminated in the urine, predominantly as unchanged drug, which makes it useful for treating urinary tract infections caused by susceptible species (<link linkend="ch0155s0033s0002li0040">40</link>). More than 75% of a dose of posaconazole is eliminated in the feces, predominantly as unchanged drug, with the remainder being excreted as glucuronidated derivatives in the urine (<link linkend="ch0155s0033s0002li0041">41</link>). Itraconazole is unusual because its major metabolite, hydroxyitraconazole, is bioactive and has a similar spectrum of activity as the parent compound (<link linkend="ch0155s0033s0002li0042">42</link>). This metabolite is found at serum concentrations about 2-fold higher than those of the parent drug (<link linkend="ch0155s0033s0002li0030">30</link>).</para>
      <para id="ch0155s0005p0006">Voriconazole is metabolized by several different hepatic cytochrome P-450 enzymes, primarily CYP-2C19, with more than 80% of a dose being eliminated as inactive metabolites in the urine (<link linkend="ch0155s0033s0002li0035">35</link>). However, as a result of a point mutation in the gene encoding this enzyme, some persons are poor metabolizers while others are extensive metabolizers. About 3 to 5% of Caucasians and 15 to 20% of non-Indian Asians are poor metabolizers (<link linkend="ch0155s0033s0002li0043">43</link>). Voriconazole blood concentrations are as much as 4-fold lower in individuals who metabolize the drug more extensively and can reach toxic levels in poor metabolizers.</para>
      <para id="ch0155s0005p0007">Isavuconazole is metabolized by CYP-3A4 and CYP-3A5 and is eliminated in the feces (<link linkend="ch0155s0033s0002li0044">44</link>). It exhibits linear pharmacokinetics and does not appear to require therapeutic drug monitoring.</para>
    </sect1>
    <sect1 id="ch0155s0006">
      <title>Drug Interactions</title>
      <anchor id="ch0155s0006a0001"/>
      <anchor id="ch0155s0006a0002"/>
      <para id="ch0155s0006p0001">Most azole antifungal agents are extensively metabolized by the human hepatic cytochrome P-450 enzyme system and are potent inhibitors of CYP-3A4; some also inhibit CYP-2C9 and CYP-2C19. Their coadministration with other drugs that are metabolized by these enzymes can result in increased blood concentrations of the azole, the interacting drug, or both (<link linkend="ch0155s0033s0002li0045">45</link>). When an azole agent is discontinued, the change in metabolism that occurs may necessitate upward or downward adjustment of the dosage of the other drugs. Administration of azoles with drugs that are potent inducers of the human cytochrome P-450 enzyme system, such as rifampin, results in a marked reduction in blood concentrations, especially with itraconazole (<link linkend="ch0155s0033s0002li0045">45</link>).</para>
    </sect1>
    <sect1 id="ch0155s0007">
      <title>Fluconazole</title>
      <anchor id="ch0155s0007a0001"/>
      <anchor id="ch0155s0007a0002"/>
      <para id="ch0155s0007p0001">Fluconazole (Diflucan, Pfizer) is a water-soluble bis-triazole available in both oral and parenteral formulations. It is used extensively as prophylaxis and in treating yeast infections, particularly in the treatment of candidiasis and cryptococcosis.</para>
      <sect2 id="ch0155s0007s0001">
        <title>Spectrum of Activity</title>
        <anchor id="ch0155s0007s0001a0001"/>
        <anchor id="ch0155s0007s0001a0002"/>
        <para id="ch0155s0007s0001p0001">Fluconazole possesses the narrowest spectrum of all the azole antifungals currently available for systemic use. It is active against most<emphasis>Candida</emphasis> spp. and <emphasis>Cryptococcus</emphasis> spp. (<link linkend="ch0155s0033s0002li0046">46</link>, <link linkend="ch0155s0033s0002li0047">47</link>). However, isolates of <emphasis>C. krusei</emphasis> are intrinsically resistant, and <emphasis>C. glabrata</emphasis> and <emphasis>C. auris</emphasis> have decreased susceptibility (<link linkend="ch0155s0033s0002li0048">48</link>). Fluconazole may have some limited <emphasis>in vitro</emphasis> activity against several dimorphic fungi in the mold or yeast phase (<emphasis>B. dermatitidis, Coccidioides</emphasis> spp., and <emphasis>H. capsulatum</emphasis>) (<link linkend="ch0155s0033s0002li0049">49</link>). Fluconazole has no activity against <emphasis>Aspergillus</emphasis> spp., <emphasis>Fusarium</emphasis> spp., or Mucorales.</para>
      </sect2>
      <sect2 id="ch0155s0007s0002">
        <title>Acquired Resistance</title>
        <anchor id="ch0155s0007s0002a0001"/>
        <anchor id="ch0155s0007s0002a0002"/>
        <para id="ch0155s0007s0002p0001">There have been few reports of resistance developing in<emphasis>C. albicans</emphasis> during short-term fluconazole treatment in patients with mucosal or deep-seated forms of candidiasis (<link linkend="ch0155s0033s0002li0050">50</link>). In contrast, many strains of <emphasis>C. glabrata</emphasis> rapidly become resistant to fluconazole during treatment (<link linkend="ch0155s0033s0002li0050">50</link>) and so do isolates of <emphasis>C. auris</emphasis> (<link linkend="ch0155s0033s0002li0051">51</link>). In persons with AIDS, resistant strains of <emphasis>C. albicans</emphasis> have appeared following repeated courses of low-dose fluconazole treatment for oral or esophageal infection. However, with the widespread use of highly active antiretroviral treatment for HIV infection, resistant strains are now rarely encountered. There are a few reports of resistant strains of <emphasis>C. neoformans</emphasis> from AIDS patients with relapsed infection following long-term maintenance treatment with fluconazole, but those cases are thought to be rare (<link linkend="ch0155s0033s0002li0052">52</link>). There are an increasing number of reports of clonal outbreaks of resistance in <emphasis>C. parapsilosis</emphasis> and <emphasis>C. tropicalis</emphasis> (<link linkend="ch0155s0033s0002li0053">53</link>–<link linkend="ch0155s0033s0002li0057">57</link>).</para>
      </sect2>
      <sect2 id="ch0155s0007s0003">
        <title>Clinical Use</title>
        <anchor id="ch0155s0007s0003a0001"/>
        <anchor id="ch0155s0007s0003a0002"/>
        <para id="ch0155s0007s0003p0001">Fluconazole is widely used in the treatment of mucosal and systemic candidiasis (<link linkend="ch0155s0033s0002li0058">58</link>), coccidioidomycosis (<link linkend="ch0155s0033s0002li0059">59</link>), and cryptococcosis (<link linkend="ch0155s0033s0002li0060">60</link>). It is also recommended for the prevention of candidiasis in high-risk adult patients in intensive care units (<link linkend="ch0155s0033s0002li0058">58</link>), as well as for the prevention of relapse of cryptococcal meningitis in persons with AIDS (<link linkend="ch0155s0033s0002li0060">60</link>). Fluconazole is an alternative for the treatment of histoplasmosis and sporotrichosis, but is less effective than itraconazole (<link linkend="ch0155s0033s0002li0061">61</link>, <link linkend="ch0155s0033s0002li0062">62</link>). Both the CLSI and EUCAST have established breakpoints for fluconazole against <emphasis>C. albicans, C. glabrata, C. parapsilosis</emphasis>, and <emphasis>C. tropicalis.</emphasis> EUCAST also has a breakpoint for <emphasis>C. dubliniensis</emphasis>.</para>
      </sect2>
      <sect2 id="ch0155s0007s0004">
        <title>Therapeutic Drug Monitoring</title>
        <anchor id="ch0155s0007s0004a0001"/>
        <anchor id="ch0155s0007s0004a0002"/>
        <para id="ch0155s0007s0004p0001">Serum concentrations of fluconazole are predictable from dosing and organ function, and routine monitoring of drug levels is not required (<link linkend="ch0155s0033s0002li0063">63</link>).</para>
      </sect2>
      <sect2 id="ch0155s0007s0005">
        <title>Toxicity and Adverse Effects</title>
        <anchor id="ch0155s0007s0005a0001"/>
        <anchor id="ch0155s0007s0005a0002"/>
        <anchor id="ch0155s0007s0005a0003"/>
        <para id="ch0155s0007s0005p0001">Fluconazole is one of the least toxic and best tolerated azole drugs, and side effects during treatment are rare. The most common patient complaints include headache, hair loss, and loss of appetite. Transient abnormalities of liver enzymes and rare serious skin reactions, including Stevens-Johnson syndrome, have been reported.</para>
      </sect2>
    </sect1>
    <sect1 id="ch0155s0008">
      <title>Isavuconazole</title>
      <anchor id="ch0155s0008a0001"/>
      <anchor id="ch0155s0008a0002"/>
      <para id="ch0155s0008p0001">Isavuconazole (Cresemba, Astellas Pharma) is a second-generation broad-spectrum triazole compound available as an oral capsule or for intravenous (IV) administration. It is prescribed as a water-soluble prodrug, isavuconium sulfate, which is hydrolyzed by plasma esterases in the blood or gastrointestinal (GI) tract into the active compound isavuconazole. The IV formulation does not require cyclodextrin, making it an option for patients with renal impairment. Its chemical structure is similar to that of fluconazole and voriconazole. Isavuconazole has good oral availability, and food uptake has no effect on the plasma concentration. The drug exhibits linear pharmacokinetics and is highly protein bound and eliminated through the GI tract, with less than 1% excreted in the urine. The half-life is approximately 80 to 100 h, which allows once-daily dosing following loading (<link linkend="ch0155s0033s0002li0064">64</link>). Tissue penetration was assessed in a rat model. The highest concentrations were reached in liver and bile, with good concentrations in brain, kidney, and intestinal mucosa and the lowest concentrations in bone and the lenses of the eyes (<link linkend="ch0155s0033s0002li0065">65</link>).</para>
      <sect2 id="ch0155s0008s0001">
        <title>Spectrum of Activity</title>
        <anchor id="ch0155s0008s0001a0001"/>
        <anchor id="ch0155s0008s0001a0002"/>
        <para id="ch0155s0008s0001p0001">Isavuconazole is active against<emphasis>Candida</emphasis> (<link linkend="ch0155s0033s0002li0066">66</link>), <emphasis>Cryptococcus</emphasis> spp. (<link linkend="ch0155s0033s0002li0067">67</link>), and non-<emphasis>Candida</emphasis> yeasts such as <emphasis>Trichosporon, Rhodotorula</emphasis>, and <emphasis>Saccharomyces</emphasis> (<link linkend="ch0155s0033s0002li0068">68</link>). Isavuconazole has good activity against <emphasis>Aspergillus</emphasis> species (<link linkend="ch0155s0033s0002li0066">66</link>, <link linkend="ch0155s0033s0002li0069">69</link>) and the endemic fungi (<link linkend="ch0155s0033s0002li0070">70</link>, <link linkend="ch0155s0033s0002li0071">71</link>). Activity against dematiaceous molds is species dependent (<link linkend="ch0155s0033s0002li0070">70</link>, <link linkend="ch0155s0033s0002li0072">72</link>, <link linkend="ch0155s0033s0002li0073">73</link>), as is the activity against the Mucorales (<link linkend="ch0155s0033s0002li0074">74</link>, <link linkend="ch0155s0033s0002li0075">75</link>). It does not have good activity against <emphasis>Scedosporium</emphasis> spp. (<link linkend="ch0155s0033s0002li0070">70</link>, <link linkend="ch0155s0033s0002li0076">76</link>), <emphasis>Lomentospora prolificans</emphasis> (<link linkend="ch0155s0033s0002li0076">76</link>), or <emphasis>Fusarium</emphasis> spp. (<link linkend="ch0155s0033s0002li0070">70</link>, <link linkend="ch0155s0033s0002li0077">77</link>).</para>
      </sect2>
      <sect2 id="ch0155s0008s0002">
        <title>Acquired Resistance</title>
        <anchor id="ch0155s0008s0002a0001"/>
        <anchor id="ch0155s0008s0002a0002"/>
        <para id="ch0155s0008s0002p0001">Clinical use of isavuconazole is just beginning, and therefore not much acquired resistance has been noted. In a study of azole-resistant isolates of<emphasis>Candida</emphasis> species, isavuconazole MICs were increased similarly to what was seen with voriconazole (<link linkend="ch0155s0033s0002li0078">78</link>). There is also evidence that the pan-azole-resistant isolates of <emphasis>Aspergillus fumigatus</emphasis> are resistant to isavuconazole as well (<link linkend="ch0155s0033s0002li0079">79</link>).</para>
      </sect2>
      <sect2 id="ch0155s0008s0003">
        <title>Clinical Use</title>
        <anchor id="ch0155s0008s0003a0001"/>
        <anchor id="ch0155s0008s0003a0002"/>
        <para id="ch0155s0008s0003p0001">In the United States, isavuconazole has been approved for the treatment of aspergillosis and mucormycosis. In the phase III clinical trial, isavuconazole was found to be noninferior to voriconazole for the treatment of invasive aspergillosis (<link linkend="ch0155s0033s0002li0069">69</link>). In the European Union it is approved for use against invasive aspergillosis and for mucormycosis in patients for whom amphotericin B is inappropriate. In a phase III trial for the treatment of candidemia, isavuconazole failed to meet noninferiority when compared to caspofungin. However, it was noninferior to fluconazole in a phase II trial of esophageal candidiasis (<link linkend="ch0155s0033s0002li0080">80</link>). In another phase III trial, IV isavuconazole followed by oral isavuconazole was compared to caspofungin followed by oral voriconazole for the treatment of candidemia or invasive candidiasis. The results did not meet the noninferiority margin. In an open-label phase III trial against endemic mycoses and <emphasis>Cryptococcus</emphasis>, isavuconazole showed good clinical efficacy (<link linkend="ch0155s0033s0002li0071">71</link>). The CLSI has not established breakpoints for isavuconazole against any species of fungi. EUCAST has established isavuconazole breakpoints for <emphasis>A. fumigatus, A. flavus, A. nidulans</emphasis>, and <emphasis>A. terreus</emphasis>.</para>
      </sect2>
      <sect2 id="ch0155s0008s0004">
        <title>Therapeutic Drug Monitoring</title>
        <anchor id="ch0155s0008s0004a0001"/>
        <anchor id="ch0155s0008s0004a0002"/>
        <para id="ch0155s0008s0004p0001">The average trough level in patient groups during the phase III clinical trials exceeded the MIC<subscript>90</subscript> of the majority of target organisms, and routine monitoring of drug levels is not currently thought to be required (<link linkend="ch0155s0033s0002li0081">81</link>).</para>
      </sect2>
      <sect2 id="ch0155s0008s0005">
        <title>Toxicity and Adverse Effects</title>
        <anchor id="ch0155s0008s0005a0001"/>
        <anchor id="ch0155s0008s0005a0002"/>
        <para id="ch0155s0008s0005p0001">Isavuconazole is well tolerated. The most frequent side effects were abdominal pain, conjunctivitis, diarrhea, rhinitis, and nasopharyngitis (<link linkend="ch0155s0033s0002li0064">64</link>). In a phase III head-to-head trial with voriconazole, fewer drug-related adverse events were reported with isavuconazole than with voriconazole (<link linkend="ch0155s0033s0002li0069">69</link>).</para>
      </sect2>
    </sect1>
    <sect1 id="ch0155s0009">
      <title>Itraconazole</title>
      <anchor id="ch0155s0009a0001"/>
      <anchor id="ch0155s0009a0002"/>
      <para id="ch0155s0009p0001">Itraconazole (Sporanox, Ortho-McNeil-Janssen Pharmaceuticals) is a lipophilic triazole drug available for oral or parenteral administration. It is extensively used, particularly in the treatment of superficial fungal infections, as well as in a range of subcutaneous and systemic infections.</para>
      <sect2 id="ch0155s0009s0001">
        <title>Spectrum of Activity</title>
        <anchor id="ch0155s0009s0001a0001"/>
        <anchor id="ch0155s0009s0001a0002"/>
        <para id="ch0155s0009s0001p0001">Itraconazole has good activity against a broad spectrum of pathogenic fungi, including<emphasis>Aspergillus</emphasis> spp. (<link linkend="ch0155s0033s0002li0082">82</link>–<link linkend="ch0155s0033s0002li0084">84</link>), <emphasis>Candida</emphasis> spp. (<link linkend="ch0155s0033s0002li0082">82</link>, <link linkend="ch0155s0033s0002li0085">85</link>, <link linkend="ch0155s0033s0002li0086">86</link>), many dematiaceous molds (<link linkend="ch0155s0033s0002li0005">5</link>), dermatophytes (<link linkend="ch0155s0033s0002li0002">2</link>–<link linkend="ch0155s0033s0002li0004">4</link>), and dimorphic fungi (<emphasis>Blastomyces</emphasis> spp., <emphasis>Coccidioides</emphasis> spp., <emphasis>Histoplasma</emphasis> spp., <emphasis>Paracoccidioides</emphasis> spp., <emphasis>T. marneffei</emphasis>, and <emphasis>Sporothrix</emphasis> spp.) (<link linkend="ch0155s0033s0002li0009">9</link>, <link linkend="ch0155s0033s0002li0010">10</link>, <link linkend="ch0155s0033s0002li0049">49</link>, <link linkend="ch0155s0033s0002li0087">87</link>). Itraconazole has modest activity against <emphasis>C. neoformans</emphasis> (<link linkend="ch0155s0033s0002li0082">82</link>), but is ineffective against <emphasis>Scedosporium</emphasis> species (<link linkend="ch0155s0033s0002li0076">76</link>) and most Mucorales (<link linkend="ch0155s0033s0002li0088">88</link>).</para>
      </sect2>
      <sect2 id="ch0155s0009s0002">
        <title>Acquired Resistance</title>
        <anchor id="ch0155s0009s0002a0001"/>
        <anchor id="ch0155s0009s0002a0002"/>
        <para id="ch0155s0009s0002p0001">Itraconazole-resistant strains of<emphasis>A. fumigatus</emphasis> have been reported following treatment (<link linkend="ch0155s0033s0002li0089">89</link>, <link linkend="ch0155s0033s0002li0090">90</link>). Of more concern are increasing reports of itraconazole resistance due to the environmentally acquired mutations in <emphasis>cyp51A</emphasis>, TR<subscript>34</subscript>/L94H, and TR<subscript>46</subscript>/Y121F/T289A (<link linkend="ch0155s0033s0002li0091">91</link>). This mutation has now been identified in isolates from Asia, Africa, North America, South America, and Australia and has become a serious problem in parts of Europe (<link linkend="ch0155s0033s0002li0092">92</link>).</para>
      </sect2>
      <sect2 id="ch0155s0009s0003">
        <title>Clinical Use</title>
        <anchor id="ch0155s0009s0003a0001"/>
        <anchor id="ch0155s0009s0003a0002"/>
        <para id="ch0155s0009s0003p0001">Itraconazole has been widely used to treat various superficial fungal infections, including the dermatophytoses, onychomycosis, pityriasis versicolor, and mucosal and cutaneous forms of candidiasis. It is also effective in patients with paracoccidioidomycosis, chromoblastomycosis, sporotrichosis, and certain forms of phaeohyphomycosis. Despite its limitations, itraconazole continues to be a drug of choice in the management of mild to moderate forms of blastomycosis and histoplasmosis (<link linkend="ch0155s0033s0002li0062">62</link>, <link linkend="ch0155s0033s0002li0093">93</link>). It was the first orally active drug for aspergillosis, but its use in seriously ill patients with life-threatening forms of this disease is not recommended (<link linkend="ch0155s0033s0002li0094">94</link>). Itraconazole is the drug of choice for long-term maintenance treatment to prevent relapse in AIDS patients with histoplasmosis (<link linkend="ch0155s0033s0002li0062">62</link>), but it is less effective than fluconazole as maintenance treatment in AIDS patients with cryptococcosis (<link linkend="ch0155s0033s0002li0060">60</link>). Although the CLSI had previously established breakpoints for itraconazole against several species of <emphasis>Candida</emphasis>, it no longer recognizes those breakpoints as valid. EUCAST has breakpoints for itraconazole against <emphasis>C. albicans, C. dubliniensis, C. parapsilosis, C. tropicalis, A. flavus, A. fumigatus, A. nidulans</emphasis>, and <emphasis>A. terreus</emphasis>.</para>
        <anchor id="ch0155s0009s0003a0003"/>
        <beginpage pagenum="2623"/>
        <para id="ch0155s0009s0003p0002">The FDA has recently approved a new formulation of itraconazole, SUBA-itraconazole (Mayne Pharma), that increases its bioavailability (<link linkend="ch0155s0033s0002li0095">95</link>). This formulation has been approved for the treatment of histoplasmosis, blastomycosis, and aspergillosis refractory to amphotericin B treatment. An inhaled formulation of itraconazole, PUR1900 (Pulmazole; Pulmatrix), is currently in phase II clinical trials for the treatment of acute bronchopulmonary aspergillosis in patients with asthma (<link linkend="ch0155s0033s0002li0096">96</link>).</para>
      </sect2>
      <sect2 id="ch0155s0009s0004">
        <title>Therapeutic Drug Monitoring</title>
        <anchor id="ch0155s0009s0004a0001"/>
        <anchor id="ch0155s0009s0004a0002"/>
        <para id="ch0155s0009s0004p0001">Absorption of the capsule formulation of itraconazole after oral administration shows marked variation between individuals. Because low serum concentrations are often predictive of treatment failure, measurement of blood levels is advisable in situations where the drug is used to treat or prevent serious invasive fungal infections (<link linkend="ch0155s0033s0002li0063">63</link>). For prophylaxis, a target trough concentration of &gt;0.5 μg/ml has been proposed; for treatment, a trough of &gt;1 to 2 μg/ml has been recommended (<link linkend="ch0155s0033s0002li0063">63</link>).</para>
      </sect2>
      <sect2 id="ch0155s0009s0005">
        <title>Toxicity and Adverse Effects</title>
        <anchor id="ch0155s0009s0005a0001"/>
        <anchor id="ch0155s0009s0005a0002"/>
        <para id="ch0155s0009s0005p0001">Most side effects associated with itraconazole are mild and reversible. The most frequently reported adverse events are headache, loss of appetite, nausea, abdominal discomfort, diarrhea, skin rashes, and transient elevations of liver enzymes. Gastrointestinal intolerance is more common with itraconazole oral solution and is sometimes severe enough to necessitate discontinuation of treatment (<link linkend="ch0155s0033s0002li0034">34</link>). Rare, but serious, side effects include Stevens-Johnson syndrome, hepatitis, and congestive heart failure.</para>
      </sect2>
    </sect1>
    <sect1 id="ch0155s0010">
      <title>Ketoconazole</title>
      <anchor id="ch0155s0010a0001"/>
      <anchor id="ch0155s0010a0002"/>
      <para id="ch0155s0010p0001">Ketoconazole (Nizoral, Ortho-McNeil-Janssen Pharmaceuticals) is a lipophilic drug formulated for oral or topical use. It is the only antifungal imidazole still available for systemic administration, but its main use is now as a topical agent.</para>
      <sect2 id="ch0155s0010s0001">
        <title>Spectrum of Activity</title>
        <anchor id="ch0155s0010s0001a0001"/>
        <anchor id="ch0155s0010s0001a0002"/>
        <para id="ch0155s0010s0001p0001">Ketoconazole has useful activity against dermatophytes (<link linkend="ch0155s0033s0002li0097">97</link>) and dimorphic fungi (<emphasis>Blastomyces</emphasis> spp., <emphasis>Coccidioides</emphasis> spp., <emphasis>Histoplasma</emphasis> spp., <emphasis>Paracoccidioides</emphasis> spp<emphasis>.,</emphasis> and <emphasis>Sporothrix</emphasis> spp.) (<link linkend="ch0155s0033s0002li0098">98</link>). It is also active against <emphasis>Candida</emphasis> spp. and <emphasis>C. neoformans</emphasis>, although it is less effective than the newer triazoles.</para>
      </sect2>
      <sect2 id="ch0155s0010s0002">
        <title>Acquired Resistance</title>
        <anchor id="ch0155s0010s0002a0001"/>
        <anchor id="ch0155s0010s0002a0002"/>
        <para id="ch0155s0010s0002p0001">Acquired resistance is rare, but several instances were documented in the 1980s among patients given long-term treatment for chronic mucocutaneous candidiasis due to<emphasis>C. albicans</emphasis>.</para>
      </sect2>
      <sect2 id="ch0155s0010s0003">
        <title>Clinical Use</title>
        <anchor id="ch0155s0010s0003a0001"/>
        <anchor id="ch0155s0010s0003a0002"/>
        <para id="ch0155s0010s0003p0001">Due to the availability of less toxic, more efficacious alternatives, ketoconazole is now little used, except in resource-limited settings. Ketoconazole remains a useful topical agent for dermatophytosis, cutaneous candidiasis, pityriasis versicolor, and seborrheic dermatitis (<link linkend="ch0155s0033s0002li0097">97</link>).</para>
      </sect2>
      <sect2 id="ch0155s0010s0004">
        <title>Toxicity and Adverse Effects</title>
        <anchor id="ch0155s0010s0004a0001"/>
        <anchor id="ch0155s0010s0004a0002"/>
        <para id="ch0155s0010s0004p0001">Unwanted effects include loss of appetite, abdominal pain, nausea, and vomiting. Transient elevations of liver enzymes are common with oral ketoconazole, and fatal hepatitis is a rare but well-recognized adverse event. High doses of ketoconazole inhibit human adrenal and testicular steroid synthesis, with clinical consequences such as alopecia, gynecomastia, and impotence.</para>
      </sect2>
    </sect1>
    <sect1 id="ch0155s0011">
      <title>Posaconazole</title>
      <anchor id="ch0155s0011a0001"/>
      <anchor id="ch0155s0011a0002"/>
      <para id="ch0155s0011p0001">Posaconazole (Noxafil, Merck) is a second-generation, broad-spectrum triazole compound which is available as an oral suspension, an IV formulation, and a tablet. The new IV formulation allows the treatment in seriously ill patients, for which there used to be a formulary advantage to voriconazole. Posaconazole is highly lipophilic and has a chemical structure similar to that of itraconazole.</para>
      <sect2 id="ch0155s0011s0001">
        <title>Spectrum of Activity</title>
        <anchor id="ch0155s0011s0001a0001"/>
        <anchor id="ch0155s0011s0001a0002"/>
        <para id="ch0155s0011s0001p0001">Posaconazole is highly active against most<emphasis>Aspergillus</emphasis> spp. (<link linkend="ch0155s0033s0002li0083">83</link>, <link linkend="ch0155s0033s0002li0099">99</link>) as well as <emphasis>Candida</emphasis> spp., <emphasis>C. neoformans</emphasis>, and <emphasis>Trichosporon</emphasis> spp. (<link linkend="ch0155s0033s0002li0047">47</link>, <link linkend="ch0155s0033s0002li0085">85</link>, <link linkend="ch0155s0033s0002li0100">100</link>–<link linkend="ch0155s0033s0002li0102">102</link>). It has potent activity against a number of dimorphic fungi, including <emphasis>Blastomyces</emphasis> spp., <emphasis>Coccidioides</emphasis> spp., <emphasis>Histoplasma</emphasis> spp., <emphasis>Paracoccidioides</emphasis> spp<emphasis>., T. marneffei</emphasis>, and <emphasis>Sporothrix</emphasis> spp. (<link linkend="ch0155s0033s0002li0049">49</link>, <link linkend="ch0155s0033s0002li0070">70</link>). It is less active against <emphasis>Fusarium</emphasis> spp. and <emphasis>Scedosporium</emphasis> spp., but appears to be effective against dematiaceous fungi (<link linkend="ch0155s0033s0002li0070">70</link>, <link linkend="ch0155s0033s0002li0076">76</link>, <link linkend="ch0155s0033s0002li0103">103</link>). Unlike most other azole antifungals, posaconazole has significant activity against some Mucorales (<link linkend="ch0155s0033s0002li0088">88</link>, <link linkend="ch0155s0033s0002li0104">104</link>–<link linkend="ch0155s0033s0002li0106">106</link>).</para>
      </sect2>
      <sect2 id="ch0155s0011s0002">
        <title>Acquired Resistance</title>
        <anchor id="ch0155s0011s0002a0001"/>
        <anchor id="ch0155s0011s0002a0002"/>
        <para id="ch0155s0011s0002p0001">Posaconazole sometimes has activity against strains of<emphasis>Aspergillus</emphasis> and <emphasis>Candida</emphasis> spp. that show resistance to itraconazole, fluconazole, and/or voriconazole (<link linkend="ch0155s0033s0002li0107">107</link>). Posaconazole resistance in <emphasis>A. fumigatus</emphasis> isolates harboring the TR<subscript>34</subscript>/L98H mutation has been demonstrated (<link linkend="ch0155s0033s0002li0108">108</link>).</para>
      </sect2>
      <sect2 id="ch0155s0011s0003">
        <title>Clinical Use</title>
        <anchor id="ch0155s0011s0003a0001"/>
        <anchor id="ch0155s0011s0003a0002"/>
        <para id="ch0155s0011s0003p0001">In the United States, posaconazole has been approved for the treatment of oropharyngeal candidiasis (including infections refractory to itraconazole and/or fluconazole), as well as for prophylaxis of invasive aspergillosis and candidiasis in high-risk patients, such as hematopoietic stem cell transplant (HSCT) recipients with graft-versus-host disease and neutropenic cancer patients. In the European Union, posaconazole has been licensed for similar indications, as well as for salvage treatment of invasive aspergillosis, coccidioidomycosis, chromoblastomycosis,<emphasis>Fusarium</emphasis> infections, and mycetoma. Other indications for which posaconazole has proved effective, but is not currently licensed, include histoplasmosis (<link linkend="ch0155s0033s0002li0109">109</link>), coccidioidomycosis in the United States (<link linkend="ch0155s0033s0002li0110">110</link>), and infections caused by Mucorales (<link linkend="ch0155s0033s0002li0106">106</link>, <link linkend="ch0155s0033s0002li0111">111</link>). The CLSI has not established breakpoints for posaconazole against any species of fungi. EUCAST has established breakpoints for posaconazole against <emphasis>C. albicans, C. dubliniensis, C. parapsilosis, C. tropicalis</emphasis>, and <emphasis>A. fumigatus</emphasis>.</para>
      </sect2>
      <sect2 id="ch0155s0011s0004">
        <title>Therapeutic Drug Monitoring</title>
        <anchor id="ch0155s0011s0004a0001"/>
        <anchor id="ch0155s0011s0004a0002"/>
        <para id="ch0155s0011s0004p0001">Similar to itraconazole and voriconazole, there appears to be a relationship between posaconazole trough serum concentrations and clinical response, and measurement of drug levels may therefore be useful (<link linkend="ch0155s0033s0002li0035">35</link>, <link linkend="ch0155s0033s0002li0063">63</link>). For prophylaxis, a target trough concentration of &gt;0.5 μg/ml has been proposed; for treatment, a trough of &gt;0.5 to 1.5 μg/ml has been suggested (<link linkend="ch0155s0033s0002li0063">63</link>). Oral uptake of posaconazole differs depending on the formulation used. It may not be necessary to monitor blood levels after either tablet administration or IV administration.</para>
      </sect2>
      <sect2 id="ch0155s0011s0005">
        <title>Toxicity and Adverse Effects</title>
        <anchor id="ch0155s0011s0005a0001"/>
        <anchor id="ch0155s0011s0005a0002"/>
        <anchor id="ch0155s0011s0005a0003"/>
        <para id="ch0155s0011s0005p0001">Posaconazole is well tolerated, even among patients receiving the drug for longer than 6 months (<link linkend="ch0155s0033s0002li0112">112</link>). The most frequently reported side effects have been gastrointestinal symptoms and headache. Transient transaminase abnormalities have also been reported. Rare cases of cholestasis or hepatic failure have occurred during treatment with posaconazole.</para>
      </sect2>
    </sect1>
    <sect1 id="ch0155s0012">
      <title>Voriconazole</title>
      <anchor id="ch0155s0012a0001"/>
      <anchor id="ch0155s0012a0002"/>
      <para id="ch0155s0012p0001">Voriconazole (Vfend, Pfizer) is a second-generation broad-spectrum triazole compound available for oral or IV administration. Its chemical structure is similar to that of fluconazole.</para>
      <sect2 id="ch0155s0012s0001">
        <title>Spectrum of Activity</title>
        <anchor id="ch0155s0012s0001a0001"/>
        <anchor id="ch0155s0012s0001a0002"/>
        <para id="ch0155s0012s0001p0001">Voriconazole is highly active against most<emphasis>Aspergillus</emphasis> spp., <emphasis>Fusarium</emphasis> spp., and <emphasis>Scedosporium</emphasis> spp. (<link linkend="ch0155s0033s0002li0070">70</link>, <link linkend="ch0155s0033s0002li0076">76</link>, <link linkend="ch0155s0033s0002li0083">83</link>, <link linkend="ch0155s0033s0002li0103">103</link>), as well as <emphasis>Candida</emphasis> spp., <emphasis>C. neoformans</emphasis>, and <emphasis>Trichosporon</emphasis> spp. (<link linkend="ch0155s0033s0002li0047">47</link>, <link linkend="ch0155s0033s0002li0052">52</link>, <link linkend="ch0155s0033s0002li0085">85</link>, <link linkend="ch0155s0033s0002li0100">100</link>, <link linkend="ch0155s0033s0002li0101">101</link>). Voriconazole has potent activity against a number of dimorphic fungi, including <emphasis>Blastomyces</emphasis> spp., <emphasis>Coccidioides</emphasis> spp., <emphasis>Histoplasma</emphasis> spp., and <emphasis>T. marneffei</emphasis> (<link linkend="ch0155s0033s0002li0070">70</link>, <link linkend="ch0155s0033s0002li0087">87</link>), as well as dematiaceous molds (<link linkend="ch0155s0033s0002li0070">70</link>). Voriconazole is ineffective against Mucorales (<link linkend="ch0155s0033s0002li0088">88</link>, <link linkend="ch0155s0033s0002li0105">105</link>).</para>
      </sect2>
      <sect2 id="ch0155s0012s0002">
        <title>Acquired Resistance</title>
        <anchor id="ch0155s0012s0002a0001"/>
        <anchor id="ch0155s0012s0002a0002"/>
        <para id="ch0155s0012s0002p0001">Some fluconazole-resistant strains of<emphasis>Candida</emphasis> spp. have shown reduced susceptibility to voriconazole, and essentially all <emphasis>C. glabrata</emphasis> isolates that are resistant to fluconazole should be considered nonsusceptible to voriconazole. <emphasis>Aspergillus</emphasis> isolates may acquire voriconazole resistance during long-term azole therapy, and environmentally acquired resistance to <emphasis>A. fumigatus</emphasis> due to a TR<subscript>34</subscript>/L98H mutation in the CYP51A gene has been reported (<link linkend="ch0155s0033s0002li0089">89</link>, <link linkend="ch0155s0033s0002li0107">107</link>, <link linkend="ch0155s0033s0002li0113">113</link>). The newly emerging mutation in <emphasis>A. fumigatus</emphasis>, TR<subscript>46</subscript>/Y121/T289A, seems to be specific for voriconazole resistance (<link linkend="ch0155s0033s0002li0089">89</link>, <link linkend="ch0155s0033s0002li0107">107</link>, <link linkend="ch0155s0033s0002li0113">113</link>).</para>
      </sect2>
      <sect2 id="ch0155s0012s0003">
        <title>Clinical Use</title>
        <anchor id="ch0155s0012s0003a0001"/>
        <anchor id="ch0155s0012s0003a0002"/>
        <para id="ch0155s0012s0003p0001">The availability of both an IV formulation and a well-absorbed oral formulation of voriconazole is a distinct advantage when treating seriously ill patients. In the United States, the drug has been approved for the treatment of invasive aspergillosis and has become the drug of choice for these infections (<link linkend="ch0155s0033s0002li0094">94</link>). It is also licensed for the treatment of candidemia in nonneutropenic patients, for disseminated infections caused by <emphasis>Candida</emphasis> spp., and for esophageal candidiasis, as well as for salvage treatment of <emphasis>Fusarium</emphasis> and <emphasis>Scedosporium</emphasis> infections. In the European Union, voriconazole has been approved for similar indications. Because voriconazole has no activity against Mucorales, its use in immunocompromised patients has sometimes been associated with breakthrough infections caused by these organisms. The CLSI has established breakpoints for voriconazole against <emphasis>C. albicans, C. krusei, C. parapsilosis, C. tropicalis</emphasis>, and <emphasis>A. fumigatus.</emphasis> EUCAST has established breakpoints for voriconazole against <emphasis>C. albicans, C. dubliniensis, C. parapsilosis, C. tropicalis, A. fumigatus</emphasis>, and <emphasis>A. nidulans</emphasis>.</para>
      </sect2>
      <sect2 id="ch0155s0012s0004">
        <title>Therapeutic Drug Monitoring</title>
        <anchor id="ch0155s0012s0004a0001"/>
        <anchor id="ch0155s0012s0004a0002"/>
        <para id="ch0155s0012s0004p0001">Voriconazole serum concentrations are highly variable, largely due to differences in the rate of metabolism between individuals, and it may be beneficial to monitor drug levels (<link linkend="ch0155s0033s0002li0035">35</link>, <link linkend="ch0155s0033s0002li0063">63</link>, <link linkend="ch0155s0033s0002li0114">114</link>). For prophylaxis, a target trough concentration of &gt;0.5 μg/ml has been proposed; for treatment, a trough of &gt;1 to 2 μg/ml has been recommended (<link linkend="ch0155s0033s0002li0063">63</link>). To avoid toxicity, trough concentrations of 6 μg/ml of voriconazole should not be exceeded.</para>
      </sect2>
      <sect2 id="ch0155s0012s0005">
        <title>Toxicity and Adverse Effects</title>
        <anchor id="ch0155s0012s0005a0001"/>
        <anchor id="ch0155s0012s0005a0002"/>
        <para id="ch0155s0012s0005p0001">Voriconazole is generally well tolerated. About 30% of patients experience transient visual disturbances and hallucinations, usually during the first week of treatment (<link linkend="ch0155s0033s0002li0114">114</link>). Other side effects include skin rashes and transient abnormalities of liver enzymes. Rare, but serious, adverse effects include Stevens-Johnson syndrome, hepatic failure, and cardiovascular events.</para>
      </sect2>
      <sect2 id="ch0155s0012s0006">
        <title>ECHINOCANDINS</title>
        <anchor id="ch0155s0012s0006a0001"/>
        <anchor id="ch0155s0012s0006a0002"/>
        <para id="ch0155s0012s0006p0001">The echinocandins are semisynthetic lipopeptide antifungal agents that target the fungal cell wall. Three echinocandins have been approved for the treatment of serious fungal infections: anidulafungin, caspofungin, and micafungin. Due to their high molecular weight and low oral bioavailability, these drugs are only available as IV preparations. They are now widely used, particularly in the treatment of candidiasis.</para>
      </sect2>
    </sect1>
    <sect1 id="ch0155s0013">
      <title>Mechanism of Action</title>
      <anchor id="ch0155s0013a0001"/>
      <anchor id="ch0155s0013a0002"/>
      <para id="ch0155s0013p0001">The echinocandins disrupt fungal cell wall synthesis by inhibiting the enzyme 1,3-β-<emphasis role="smallcaps">D</emphasis>-glucan synthase. This results in inhibition of the formation of 1,3-β-<emphasis role="smallcaps">D</emphasis>-glucan, an essential polysaccharide component of the cell wall of susceptible fungi. Inhibition leads to osmotic lysis of the cell and eventual cell death. Echinocandin drugs bind to Fksp, the major subunit of 1,3-β-<emphasis role="smallcaps">D</emphasis>-glucan synthase, which is encoded by three <emphasis>FKS</emphasis> genes in <emphasis>Candida</emphasis> spp. (<link linkend="ch0155s0033s0002li0115">115</link>). The echinocandins are fungicidal for <emphasis>Candida</emphasis> spp., but fungistatic for <emphasis>Aspergillus</emphasis> spp., where they block the growth of the apical tips of the hyphae (<link linkend="ch0155s0033s0002li0116">116</link>).</para>
    </sect1>
    <sect1 id="ch0155s0014">
      <title>Spectrum of Activity</title>
      <anchor id="ch0155s0014a0001"/>
      <anchor id="ch0155s0014a0002"/>
      <para id="ch0155s0014p0001">The echinocandins have a limited spectrum of activity. They are highly active against a broad range of<emphasis>Candida</emphasis> spp., including fluconazole-resistant strains (<link linkend="ch0155s0033s0002li0085">85</link>, <link linkend="ch0155s0033s0002li0117">117</link>, <link linkend="ch0155s0033s0002li0118">118</link>). <emphasis>C. parapsilosis, C. lusitaniae</emphasis>, and <emphasis>C. guilliermondii</emphasis> have higher MIC values to the echinocandins, but patients with these species respond well to treatment if the MIC is within the susceptible range (<link linkend="ch0155s0033s0002li0117">117</link>, <link linkend="ch0155s0033s0002li0119">119</link>). The echinocandins are also active against <emphasis>Aspergillus</emphasis> spp., including those that are intrinsically resistant to amphotericin B (<link linkend="ch0155s0033s0002li0120">120</link>, <link linkend="ch0155s0033s0002li0121">121</link>).</para>
      <para id="ch0155s0014p0002">The echinocandins are ineffective against fungi that lack a significant amount of 1,3-β-<emphasis role="smallcaps">D</emphasis>-glucan in their cell wall, including <emphasis>C. neoformans</emphasis> and <emphasis>Trichosporon</emphasis> spp., as well as <emphasis>Fusarium</emphasis> spp. and the Mucorales (<link linkend="ch0155s0033s0002li0122">122</link>). Micafungin has been reported to be active against the mycelial forms of several dimorphic fungi, including <emphasis>B. dermatitidis</emphasis> and <emphasis>H. capsulatum</emphasis>, but is ineffective against the tissue forms of these pathogens (<link linkend="ch0155s0033s0002li0123">123</link>).</para>
    </sect1>
    <sect1 id="ch0155s0015">
      <title>Acquired Resistance</title>
      <anchor id="ch0155s0015a0001"/>
      <anchor id="ch0155s0015a0002"/>
      <para id="ch0155s0015p0001">Acquired resistance is rare at present, but resistant strains of several<emphasis>Candida</emphasis> spp. have been recovered from patients failing echinocandin treatment (<link linkend="ch0155s0033s0002li0051">51</link>, <link linkend="ch0155s0033s0002li0124">124</link>, <link linkend="ch0155s0033s0002li0125">125</link>). Resistance has been associated with acquisition of mutations in the <emphasis>FKS1</emphasis> and/or <emphasis>FKS2</emphasis> genes that led to amino acid substitutions within the Fks1p and Fks2p subunits of 1,3-β-<emphasis role="smallcaps">D</emphasis>-glucan synthase (<link linkend="ch0155s0033s0002li0118">118</link>, <link linkend="ch0155s0033s0002li0124">124</link>, <link linkend="ch0155s0033s0002li0126">126</link>). These changes result in altered drug binding and confer cross-resistance to all echinocandin drugs. Mutations in the <emphasis>FKS1</emphasis> and <emphasis>FKS2</emphasis> genes are responsible for reduced susceptibility to caspofungin, micafungin, and anidulafungin in most <emphasis>Candida</emphasis> species (<link linkend="ch0155s0033s0002li0126">126</link>). The highest rates of resistance have been detected in <emphasis>C. glabrata</emphasis>, especially in strains already resistant to fluconazole (<link linkend="ch0155s0033s0002li0118">118</link>, <link linkend="ch0155s0033s0002li0124">124</link>, <link linkend="ch0155s0033s0002li0127">127</link>).</para>
      <anchor id="ch0155s0015a0003"/>
      <beginpage pagenum="2625"/>
    </sect1>
    <sect1 id="ch0155s0016">
      <title>Pharmacokinetics</title>
      <anchor id="ch0155s0016a0001"/>
      <anchor id="ch0155s0016a0002"/>
      <para id="ch0155s0016p0001">Blood concentrations of all three echinocandins increase in proportion to dosage (<link linkend="ch0155s0033s0002li0035">35</link>, <link linkend="ch0155s0033s0002li0128">128</link>). These drugs are extensively distributed to body tissues, but levels in the CSF and ocular tissue are negligible. The predominant differences among these agents lie in their metabolism and half-life. Caspofungin and micafungin are largely metabolized by the liver and eliminated as inactive metabolites in the feces and urine (<link linkend="ch0155s0033s0002li0035">35</link>, <link linkend="ch0155s0033s0002li0129">129</link>). Anidulafungin is not eliminated by hepatic metabolism, but undergoes slow nonenzymatic degradation in the blood to an inactive open-ring peptide (<link linkend="ch0155s0033s0002li0130">130</link>). Less than 1 to 3% of an echinocandin dose is excreted unchanged in the urine (<link linkend="ch0155s0033s0002li0035">35</link>, <link linkend="ch0155s0033s0002li0129">129</link>, <link linkend="ch0155s0033s0002li0131">131</link>, <link linkend="ch0155s0033s0002li0132">132</link>). In adults, the half-life of caspofungin is about 9 to 10 h (<link linkend="ch0155s0033s0002li0132">132</link>), while that of micafungin is 13 h (<link linkend="ch0155s0033s0002li0133">133</link>) and that of anidulafungin is 18 to 27 h (<link linkend="ch0155s0033s0002li0130">130</link>). The three echinocandins have a shorter half-life in children (<link linkend="ch0155s0033s0002li0134">134</link>). The 24-h area under the concentration-time curve (AUC)/MIC is a good indicator of the exposure-response relationship, with a ratio that should exceed 10 to 20 (<link linkend="ch0155s0033s0002li0135">135</link>).</para>
    </sect1>
    <sect1 id="ch0155s0017">
      <title>Drug Interactions</title>
      <anchor id="ch0155s0017a0001"/>
      <anchor id="ch0155s0017a0002"/>
      <para id="ch0155s0017p0001">The echinocandins do not interact with the human hepatic cytochrome P-450 system, and their use has been associated with very few significant drug interactions.</para>
    </sect1>
    <sect1 id="ch0155s0018">
      <title>Therapeutic Drug Monitoring</title>
      <anchor id="ch0155s0018a0001"/>
      <anchor id="ch0155s0018a0002"/>
      <para id="ch0155s0018p0001">At this time, there is no established relationship between efficacy or toxicity of the echinocandins and serum concentrations (<link linkend="ch0155s0033s0002li0035">35</link>, <link linkend="ch0155s0033s0002li0063">63</link>, <link linkend="ch0155s0033s0002li0136">136</link>). Routine monitoring of serum levels during treatment with these drugs is not required.</para>
    </sect1>
    <sect1 id="ch0155s0019">
      <title>Toxicity and Adverse Effects</title>
      <anchor id="ch0155s0019a0001"/>
      <anchor id="ch0155s0019a0002"/>
      <para id="ch0155s0019p0001">As a class, the echinocandins are well tolerated, and their use is associated with very few significant adverse effects (<link linkend="ch0155s0033s0002li0128">128</link>, <link linkend="ch0155s0033s0002li0131">131</link>–<link linkend="ch0155s0033s0002li0133">133</link>). The most common side effects are gastrointestinal in nature, but only occur in around 5% of patients. Occasional cases of infusion-related pain and phlebitis have been noted with anidulafungin and micafungin, but these are less common with caspofungin. Transient elevations of liver enzymes have been reported in a few patients.</para>
    </sect1>
    <sect1 id="ch0155s0020">
      <title>Anidulafungin</title>
      <anchor id="ch0155s0020a0001"/>
      <anchor id="ch0155s0020a0002"/>
      <para id="ch0155s0020p0001">Anidulafungin (Ecalta, Eraxis, Pfizer) was the first echinocandin to go into development and the most recent to be licensed for clinical use. It differs from caspofungin and micafungin in that it is insoluble in water. Anidulafungin is derived from a fermentation product of<emphasis>Aspergillus nidulans</emphasis> and is formulated for IV infusion.</para>
      <sect2 id="ch0155s0020s0001">
        <title>Clinical Use</title>
        <anchor id="ch0155s0020s0001a0001"/>
        <anchor id="ch0155s0020s0001a0002"/>
        <para id="ch0155s0020s0001p0001">In the United States, anidulafungin is currently approved for the treatment of esophageal candidiasis, candidemia, and two invasive forms of candidiasis (abdominal abscesses and peritonitis). In the European Union, anidulafungin is approved for the treatment of invasive candidiasis in nonneutropenic patients. Anidulafungin has not been evaluated in sufficient numbers of neutropenic patients to determine its effectiveness in that group. The CLSI has established breakpoints for anidulafungin against<emphasis>C. albicans, C. glabrata, C. guilliermondii, C. krusei, C. parapsilosis</emphasis>, and <emphasis>C. tropicalis.</emphasis> EUCAST has established breakpoints for anidulafungin against <emphasis>C. albicans, C. glabrata, C. krusei, C. parapsilosis</emphasis>, and <emphasis>C. tropicalis</emphasis>.</para>
      </sect2>
    </sect1>
    <sect1 id="ch0155s0021">
      <title>Caspofungin</title>
      <anchor id="ch0155s0021a0001"/>
      <anchor id="ch0155s0021a0002"/>
      <para id="ch0155s0021p0001">Caspofungin (Cancidas, Merck) is a water-soluble lipopeptide, derived from a fermentation product of<emphasis>Glarea lozoyensis.</emphasis> It is formulated for IV infusion.</para>
      <sect2 id="ch0155s0021s0001">
        <title>Clinical Use</title>
        <anchor id="ch0155s0021s0001a0001"/>
        <anchor id="ch0155s0021s0001a0002"/>
        <para id="ch0155s0021s0001p0001">In the United States, caspofungin is currently approved for the treatment of esophageal candidiasis, candidemia, and certain invasive forms of candidiasis, including abdominal abscesses, peritonitis, and pleural space infections. Caspofungin is also licensed for the salvage treatment of invasive aspergillosis in patients who have failed to respond to or are intolerant of other antifungal agents. Caspofungin is approved for the empiric treatment of presumed fungal infections in febrile neutropenic patients. It has similar indications in the European Union, with a license for the treatment of invasive candidiasis in adult and pediatric patients, salvage treatment of aspergillosis, and empiric treatment of febrile neutropenia in adult or pediatric patients. The CLSI has established breakpoints for caspofungin against<emphasis>C. albicans, C. glabrata, C. guilliermondii, C. krusei, C. parapsilosis</emphasis>, and <emphasis>C. tropicalis.</emphasis> EUCAST has no breakpoints for caspofungin and does not recommend it be used for <emphasis>in vitro</emphasis> testing, due to testing inconsistencies.</para>
      </sect2>
    </sect1>
    <sect1 id="ch0155s0022">
      <title>Micafungin</title>
      <anchor id="ch0155s0022a0001"/>
      <anchor id="ch0155s0022a0002"/>
      <para id="ch0155s0022p0001">Micafungin (Mycamine, Astellas Pharma, Fujisawa Healthcare) is a water-soluble antifungal agent, derived from a fermentation product of<emphasis>Coleophoma empetri.</emphasis> It is formulated for IV administration.</para>
      <sect2 id="ch0155s0022s0001">
        <title>Clinical Use</title>
        <anchor id="ch0155s0022s0001a0001"/>
        <anchor id="ch0155s0022s0001a0002"/>
        <para id="ch0155s0022s0001p0001">In the United States, micafungin is currently approved in adults for the treatment of esophageal candidiasis, candidemia, and several invasive forms of candidiasis, including abdominal abscesses and peritonitis, and for prophylaxis of<emphasis>Candida</emphasis> infections in HSCT patients. In the European Union, the drug is approved for the treatment of esophageal candidiasis in adults and for invasive candidiasis in adults and children, including neonates. In addition, micafungin is licensed as prophylactic treatment to prevent <emphasis>Candida</emphasis> infections in HSCT recipients in the United States and European Union. In Japan, the license includes respiratory and GI mycosis due to <emphasis>Aspergillus</emphasis> spp. Micafungin does have a black box warning in the European Union due to the development of hepatic tumors in rats following prolonged use, but this has not been seen in patients postmarketing. The CLSI has established breakpoints for micafungin against <emphasis>C. albicans, C. glabrata, C. guilliermondii, C. krusei, C. parapsilosis</emphasis>, and <emphasis>C. tropicalis.</emphasis> EUCAST has established breakpoints for anidulafungin against <emphasis>C. albicans, C. glabrata</emphasis>, and <emphasis>C. parapsilosis</emphasis>.</para>
      </sect2>
      <sect2 id="ch0155s0022s0002">
        <title>POLYENES</title>
        <anchor id="ch0155s0022s0002a0001"/>
        <anchor id="ch0155s0022s0002a0002"/>
        <para id="ch0155s0022s0002p0001">Around 100 polyene antibiotics have been described, but few have been developed for clinical use. Amphotericin B and its lipid formulations are used for the treatment of systemic fungal infections. Nystatin, natamycin, and mepartricin are topical polyene agents used in the treatment of oral, vaginal, and ocular fungal infections. A liposomal formulation of nystatin entered clinical trials, but its development has ceased. The polyenes are large molecules that consist of a closed macrolide lactone ring. One side of the ring is composed of a rigid lipophilic chain with a variable number of conjugated double bonds, and on the opposite side there are a similar number of hydroxyl groups. Thus, the molecule is amphipathic and this feature of its structure is believed to be important in its mechanism of action.</para>
        <anchor id="ch0155s0022s0002a0003"/>
        <beginpage pagenum="2626"/>
      </sect2>
    </sect1>
    <sect1 id="ch0155s0023">
      <title>Mechanism of Action</title>
      <anchor id="ch0155s0023a0001"/>
      <anchor id="ch0155s0023a0002"/>
      <para id="ch0155s0023p0001">The polyenes bind to sterols, principally ergosterol, in the membranes of susceptible fungal cells, causing impairment of membrane barrier function, leakage of cell constituents, metabolic disruption, and cell death (<link linkend="ch0155s0033s0002li0137">137</link>). In addition to its membrane-permeabilizing effects, amphotericin B can cause oxidative damage to fungal cells through a cascade of oxidative reactions linked to lipoperoxidation of the cell membrane.</para>
    </sect1>
    <sect1 id="ch0155s0024">
      <title>Amphotericin B</title>
      <anchor id="ch0155s0024a0001"/>
      <anchor id="ch0155s0024a0002"/>
      <para id="ch0155s0024p0001">Amphotericin B (Fungizone, Apothecon) is a fermentation product of<emphasis>Streptomyces nodosus</emphasis> available for IV infusion. The conventional micellar suspension formulation of this drug (amphotericin B deoxycholate) is often associated with serious toxic side effects, particularly renal damage. During the 1990s, three new lipid-associated formulations of amphotericin B were developed in an effort to alleviate the infusion-related toxicity of the agent. These are liposomal amphotericin B (AmBisome, Astellas Pharma, Gilead Sciences), in which the drug is encapsulated in phospholipid-containing liposomes; amphotericin B lipid complex (ABLC) (Abelcet, Enzon Pharmaceuticals), in which the drug is complexed with phospholipids to produce ribbon-like structures; and amphotericin B colloidal dispersion (ABCD) (Amphotec, Three Rivers Pharmaceuticals), in which the drug is packaged into small lipid disks containing cholesterol sulfate. These formulations possess the same broad spectrum of activity as the micellar suspension, but are less nephrotoxic (<link linkend="ch0155s0033s0002li0138">138</link>). There is also an encochleated amphotericin B in development (MAT2203, Matinas Biopharma). This lipid-based delivery mechanism allows for oral administration and leads to good tissue penetration (<link linkend="ch0155s0033s0002li0139">139</link>, <link linkend="ch0155s0033s0002li0140">140</link>). A phase II clinical trial against refractory mucocutaneous candidiasis is under way, as is a phase I/II trial for the treatment of cryptococcal meningitis in HIV-positive patients (<link linkend="ch0155s0033s0002li0141">141</link>).</para>
      <sect2 id="ch0155s0024s0001">
        <title>Spectrum of Activity</title>
        <anchor id="ch0155s0024s0001a0001"/>
        <anchor id="ch0155s0024s0001a0002"/>
        <para id="ch0155s0024s0001p0001">Amphotericin B is active against a broad spectrum of pathogenic fungi, including most<emphasis>Aspergillus</emphasis> spp. (<link linkend="ch0155s0033s0002li0094">94</link>, <link linkend="ch0155s0033s0002li0142">142</link>), <emphasis>Candida</emphasis> spp. (<link linkend="ch0155s0033s0002li0085">85</link>, <link linkend="ch0155s0033s0002li0086">86</link>), <emphasis>Cryptococcus</emphasis> spp. (<link linkend="ch0155s0033s0002li0047">47</link>, <link linkend="ch0155s0033s0002li0052">52</link>, <link linkend="ch0155s0033s0002li0067">67</link>), and the Mucorales (<link linkend="ch0155s0033s0002li0088">88</link>, <link linkend="ch0155s0033s0002li0105">105</link>). However, most isolates of <emphasis>A. terreus</emphasis> are clinically resistant to amphotericin B (<link linkend="ch0155s0033s0002li0143">143</link>, <link linkend="ch0155s0033s0002li0144">144</link>), as are isolates of <emphasis>A. lentulus</emphasis>, a new sibling species of <emphasis>A. fumigatus</emphasis> (<link linkend="ch0155s0033s0002li0145">145</link>). <emphasis>C. krusei</emphasis> and <emphasis>C. lusitaniae</emphasis> also demonstrate reduced susceptibility to amphotericin B. Amphotericin B is effective against the dimorphic fungi (<emphasis>Blastomyces</emphasis> spp., <emphasis>Coccidioides</emphasis> spp., <emphasis>Histoplasma</emphasis> spp., <emphasis>Paracoccidioides</emphasis> spp.) and many dematiaceous fungi (<link linkend="ch0155s0033s0002li0087">87</link>, <link linkend="ch0155s0033s0002li0146">146</link>). Strains of <emphasis>Scedosporium</emphasis> spp., <emphasis>L. prolificans, Fusarium</emphasis> spp., and <emphasis>Trichosporon</emphasis> spp. are often intrinsically resistant to amphotericin B (<link linkend="ch0155s0033s0002li0076">76</link>, <link linkend="ch0155s0033s0002li0101">101</link>, <link linkend="ch0155s0033s0002li0147">147</link>).</para>
      </sect2>
      <sect2 id="ch0155s0024s0002">
        <title>Acquired Resistance</title>
        <anchor id="ch0155s0024s0002a0001"/>
        <anchor id="ch0155s0024s0002a0002"/>
        <para id="ch0155s0024s0002p0001">Acquired resistance is rare, but amphotericin B-resistant strains of<emphasis>C. albicans, C. glabrata, C. guilliermondii, C. tropicalis, Cryptococcus neoformans</emphasis>, and especially <emphasis>C. lusitaniae</emphasis> with alterations in the cell membrane, including reduced amounts of ergosterol, have been reported following prolonged treatment (<link linkend="ch0155s0033s0002li0148">148</link>). Resistance is also seen in the emerging <emphasis>Candida</emphasis> species <emphasis>C. haemulonii, C. duobushaemulonii</emphasis>, and <emphasis>C. auris</emphasis> (<link linkend="ch0155s0033s0002li0149">149</link>).</para>
      </sect2>
      <sect2 id="ch0155s0024s0003">
        <title>Pharmacokinetics</title>
        <anchor id="ch0155s0024s0003a0001"/>
        <anchor id="ch0155s0024s0003a0002"/>
        <para id="ch0155s0024s0003p0001">Amphotericin B is poorly absorbed after oral administration and must be administered as a slow IV infusion. The drug is widely distributed to many tissues, with the highest concentrations being found in the liver, spleen, and kidneys. Levels in the CSF are less than 5% of the simultaneous blood concentration. Amphotericin B is mostly excreted as unchanged drug in the urine (21%) and feces (42%) (<link linkend="ch0155s0033s0002li0150">150</link>). No metabolites have been identified. The drug is cleared very slowly, with the conventional deoxycholate formulation having a terminal half-life of around 127 h.</para>
        <para id="ch0155s0024s0003p0002">The pharmacokinetics of lipid-based formulations of amphotericin B are quite diverse. Maximal serum concentrations of the liposomal formulation are much higher than those of the deoxycholate formulation, while levels of ABCD and ABLC are lower due to more rapid distribution of the drug to tissue (<link linkend="ch0155s0033s0002li0138">138</link>, <link linkend="ch0155s0033s0002li0150">150</link>). Administration of lipid-associated formulations of amphotericin B results in higher drug concentrations in the liver and spleen than are achieved with the conventional formulation (<link linkend="ch0155s0033s0002li0151">151</link>). Renal concentrations of the drug are lower, and the nephrotoxic side effects are greatly reduced (<link linkend="ch0155s0033s0002li0152">152</link>).</para>
      </sect2>
      <sect2 id="ch0155s0024s0004">
        <title>Clinical Use</title>
        <anchor id="ch0155s0024s0004a0001"/>
        <anchor id="ch0155s0024s0004a0002"/>
        <para id="ch0155s0024s0004p0001">Although other agents have subsequently been introduced, amphotericin B remains the treatment of choice for many serious fungal infections, including blastomycosis, coccidioidomycosis, histoplasmosis, sporotrichosis, cryptococcosis, and mucormycosis (<link linkend="ch0155s0033s0002li0059">59</link>–<link linkend="ch0155s0033s0002li0062">62</link>, <link linkend="ch0155s0033s0002li0093">93</link>). However, with the advent of voriconazole and the echinocandins, amphotericin B is no longer regarded as the drug of first choice for many cases of aspergillosis or candidiasis. The three lipid-based formulations of amphotericin B are currently licensed for treatment of invasive fungal infections in patients who are refractory to, or intolerant of, conventional amphotericin B. In addition, liposomal amphotericin B is licensed for the treatment of cryptococcal meningitis in persons with AIDS, as well as for the empirical treatment of presumed fungal infection in febrile neutropenic patients. Clinical experience with these preparations has demonstrated that they are safer and no less active than the conventional formulation, and for some infections, they are more effective, especially since the reduced toxicity allows them to be used at a higher dose. The CLSI has not established breakpoints for amphotericin B against any fungi. EUCAST has established amphotericin B breakpoints against <emphasis>C. albicans, C. dubliniensis, C. glabrata, C. krusei, C. parapsilosis, C. tropicalis, A. fumigatus</emphasis>, and <emphasis>A. niger</emphasis>.</para>
      </sect2>
      <sect2 id="ch0155s0024s0005">
        <title>Drug Interactions</title>
        <anchor id="ch0155s0024s0005a0001"/>
        <anchor id="ch0155s0024s0005a0002"/>
        <para id="ch0155s0024s0005p0001">Amphotericin B can augment the nephrotoxicity of many other agents, including aminoglycoside antibiotics and cyclosporine.</para>
      </sect2>
      <sect2 id="ch0155s0024s0006">
        <title>Therapeutic Drug Monitoring</title>
        <anchor id="ch0155s0024s0006a0001"/>
        <anchor id="ch0155s0024s0006a0002"/>
        <para id="ch0155s0024s0006p0001">Serum and tissue concentrations of amphotericin B show marked variation with formulation, especially among the lipid-based products, and there are few data relating either efficacy or toxicity to blood levels. Therefore, there is no need to monitor serum concentrations of amphotericin B during therapy (<link linkend="ch0155s0033s0002li0035">35</link>, <link linkend="ch0155s0033s0002li0063">63</link>). However, due to the risk of toxicity, kidney function should be monitored.</para>
        <anchor id="ch0155s0024s0006a0003"/>
        <beginpage pagenum="2627"/>
      </sect2>
      <sect2 id="ch0155s0024s0007">
        <title>Toxicity and Adverse Effects</title>
        <anchor id="ch0155s0024s0007a0001"/>
        <anchor id="ch0155s0024s0007a0002"/>
        <para id="ch0155s0024s0007p0001">Amphotericin B deoxycholate causes infusion-related reactions, including hypotension, fever, rigors, and chills, in approximately 70% of patients (<link linkend="ch0155s0033s0002li0138">138</link>). The major adverse effect of the drug is nephrotoxicity. This is dose related and may occur in more than 80% of patients receiving treatment. The lipid-associated formulations all lower the risk of amphotericin B-induced renal failure (<link linkend="ch0155s0033s0002li0150">150</link>, <link linkend="ch0155s0033s0002li0152">152</link>). However, infusion-related side effects, such as hypoxia and chills, are more common in patients treated with ABCD. In contrast, infusion-related reactions are uncommon in patients receiving liposomal amphotericin B or ABLC (<link linkend="ch0155s0033s0002li0138">138</link>, <link linkend="ch0155s0033s0002li0150">150</link>, <link linkend="ch0155s0033s0002li0152">152</link>).</para>
      </sect2>
      <sect2 id="ch0155s0024s0008">
        <title>OTHER MISCELLANEOUS AGENTS</title>
        <anchor id="ch0155s0024s0008a0001"/>
        <anchor id="ch0155s0024s0008a0002"/>
      </sect2>
    </sect1>
    <sect1 id="ch0155s0025">
      <title>Flucytosine</title>
      <anchor id="ch0155s0025a0001"/>
      <anchor id="ch0155s0025a0002"/>
      <para id="ch0155s0025p0001">Flucytosine (5-fluorocytosine; Ancobon, Valeant Pharmaceuticals) is a synthetic fluorinated analogue of cytosine and the only available antifungal agent acting as an antimetabolite. In the United States, flucytosine is available as oral tablets; elsewhere it is also available as an infusion for parenteral administration.</para>
      <sect2 id="ch0155s0025s0001">
        <title>Mechanism of Action</title>
        <anchor id="ch0155s0025s0001a0001"/>
        <anchor id="ch0155s0025s0001a0002"/>
        <para id="ch0155s0025s0001p0001">Flucytosine disrupts pyrimidine metabolism and thus the synthesis of DNA, RNA, and proteins within susceptible fungal cells. Flucytosine is transported into these cells by the enzyme cytosine permease and there converted by cytosine deaminase to 5-fluorouracil (5-FU). Two mechanisms then account for the antifungal activity. The first involves the conversion of 5-FU into 5-fluoruridine triphosphate, which is incorporated into fungal RNA in place of uridylic acid, with resulting inhibition of protein synthesis. The second mechanism involves the conversion of 5-FU to 5-fluorodeoxyuridine monophosphate, which blocks the enzyme thymidylate synthetase, causing inhibition of fungal DNA synthesis. Fungi lacking cytosine deaminase are intrinsically resistant to flucytosine.</para>
      </sect2>
      <sect2 id="ch0155s0025s0002">
        <title>Spectrum of Activity</title>
        <anchor id="ch0155s0025s0002a0001"/>
        <anchor id="ch0155s0025s0002a0002"/>
        <para id="ch0155s0025s0002p0001">Flucytosine has a narrow spectrum of activity. It includes<emphasis>Candida</emphasis> spp., <emphasis>C. neoformans</emphasis>, and some dematiaceous fungi causing chromoblastomycosis (<link linkend="ch0155s0033s0002li0047">47</link>, <link linkend="ch0155s0033s0002li0052">52</link>, <link linkend="ch0155s0033s0002li0085">85</link>, <link linkend="ch0155s0033s0002li0086">86</link>, <link linkend="ch0155s0033s0002li0146">146</link>). Primary resistance to flucytosine is very uncommon among <emphasis>Candida</emphasis> spp., occurring in around 2 to 3% of isolates (<link linkend="ch0155s0033s0002li0085">85</link>, <link linkend="ch0155s0033s0002li0086">86</link>, <link linkend="ch0155s0033s0002li0153">153</link>).</para>
      </sect2>
      <sect2 id="ch0155s0025s0003">
        <title>Acquired Resistance</title>
        <anchor id="ch0155s0025s0003a0001"/>
        <anchor id="ch0155s0025s0003a0002"/>
        <para id="ch0155s0025s0003p0001">Monotherapy with flucytosine often leads to the rapid induction of resistance among<emphasis>Candida</emphasis> spp. and <emphasis>C. neoformans</emphasis> (<link linkend="ch0155s0033s0002li0154">154</link>).</para>
      </sect2>
      <sect2 id="ch0155s0025s0004">
        <title>Pharmacokinetics</title>
        <anchor id="ch0155s0025s0004a0001"/>
        <anchor id="ch0155s0025s0004a0002"/>
        <para id="ch0155s0025s0004p0001">Flucytosine is rapidly and almost completely absorbed after oral administration. The drug is widely distributed, with levels in most body tissues and fluids usually exceeding 50% of the simultaneous blood concentration (<link linkend="ch0155s0033s0002li0154">154</link>). Flucytosine is primarily eliminated by renal excretion of unchanged drug. The serum half-life is between 3 and 6 h, but may be greatly extended in renal failure, necessitating modification of the dosage regimen.</para>
      </sect2>
      <sect2 id="ch0155s0025s0005">
        <title>Clinical Use</title>
        <anchor id="ch0155s0025s0005a0001"/>
        <anchor id="ch0155s0025s0005a0002"/>
        <para id="ch0155s0025s0005p0001">Due to the risk of resistance, flucytosine is rarely administered as a single agent. It is most commonly used in combination with amphotericin B in the treatment of candidiasis and cryptococcosis (<link linkend="ch0155s0033s0002li0058">58</link>, <link linkend="ch0155s0033s0002li0060">60</link>). Combination treatment with fluconazole has also been shown to be effective in AIDS-associated cryptococcal meningitis (<link linkend="ch0155s0033s0002li0060">60</link>). Although the CLSI had previously established breakpoints for flucytosine against several species of <emphasis>Candida</emphasis>, it no longer recognizes those breakpoints as valid. EUCAST does not have breakpoints for flucytosine against any species of fungi.</para>
      </sect2>
      <sect2 id="ch0155s0025s0006">
        <title>Drug Interactions</title>
        <anchor id="ch0155s0025s0006a0001"/>
        <anchor id="ch0155s0025s0006a0002"/>
        <para id="ch0155s0025s0006p0001">The antifungal activity of flucytosine is competitively inhibited by cytarabine (cytosine arabinoside), and the two drugs should not be administered together (<link linkend="ch0155s0033s0002li0154">154</link>). Nephrotoxic drugs, such as amphotericin B, decrease the elimination of flucytosine, and serum concentrations of the latter should be monitored when these agents are administered together. Flucytosine is myelosuppressive (see below) and should be used with caution in patients receiving other drugs, such as zidovudine, that could enhance its immunosuppressive side effects.</para>
      </sect2>
      <sect2 id="ch0155s0025s0007">
        <title>Therapeutic Drug Monitoring</title>
        <anchor id="ch0155s0025s0007a0001"/>
        <anchor id="ch0155s0025s0007a0002"/>
        <para id="ch0155s0025s0007p0001">Regular monitoring of serum drug concentrations of flucytosine is advisable to reduce the risk of hepatotoxicity and hematological toxicity; this is essential when there is renal impairment. To avoid toxicity, a peak concentration of 100 μg/ml of flucytosine should not be exceeded (<link linkend="ch0155s0033s0002li0136">136</link>). In contrast to toxicity, there are few data relating efficacy to blood levels for flucytosine. A reasonable goal is to maintain a post-dose concentration of &gt;25 μg/ml but &lt;100 μg/ml (<link linkend="ch0155s0033s0002li0063">63</link>, <link linkend="ch0155s0033s0002li0136">136</link>).</para>
      </sect2>
      <sect2 id="ch0155s0025s0008">
        <title>Toxicity and Adverse Effects</title>
        <anchor id="ch0155s0025s0008a0001"/>
        <anchor id="ch0155s0025s0008a0002"/>
        <para id="ch0155s0025s0008p0001">The most common, and least harmful, side effects of flucytosine are gastrointestinal, and include nausea, diarrhea, vomiting, and abdominal pain. The most severe adverse effects include bone marrow depression and hepatotoxicity (<link linkend="ch0155s0033s0002li0154">154</link>). These complications are more likely to occur if excessively high blood concentrations are maintained.</para>
      </sect2>
    </sect1>
    <sect1 id="ch0155s0026">
      <title>Griseofulvin</title>
      <anchor id="ch0155s0026a0001"/>
      <anchor id="ch0155s0026a0002"/>
      <para id="ch0155s0026p0001">Griseofulvin (Gris-PEG, Pedinol Pharmacal Inc.) is an antifungal antibiotic derived from a number of<emphasis>Penicillium</emphasis> species, including <emphasis>P. griseofulvum.</emphasis> Introduced in 1958, oral griseofulvin transformed the treatment of dermatophytosis.</para>
      <sect2 id="ch0155s0026s0001">
        <title>Mechanism of Action</title>
        <anchor id="ch0155s0026s0001a0001"/>
        <anchor id="ch0155s0026s0001a0002"/>
        <para id="ch0155s0026s0001p0001">Griseofulvin is a fungistatic drug which binds to microtubular proteins and inhibits fungal cell mitosis (<link linkend="ch0155s0033s0002li0155">155</link>).</para>
      </sect2>
      <sect2 id="ch0155s0026s0002">
        <title>Spectrum of Activity</title>
        <anchor id="ch0155s0026s0002a0001"/>
        <anchor id="ch0155s0026s0002a0002"/>
        <para id="ch0155s0026s0002p0001">The spectrum of useful activity is restricted to dermatophytes causing skin, nail, and hair infections (<emphasis>Epidermophyton, Microsporum, Nannizzia</emphasis>, and <emphasis>Trichophyton</emphasis>) (<link linkend="ch0155s0033s0002li0002">2</link>, <link linkend="ch0155s0033s0002li0003">3</link>). Resistance has rarely been reported.</para>
      </sect2>
      <sect2 id="ch0155s0026s0003">
        <title>Pharmacokinetics</title>
        <anchor id="ch0155s0026s0003a0001"/>
        <anchor id="ch0155s0026s0003a0002"/>
        <para id="ch0155s0026s0003p0001">Absorption of griseofulvin from the gastrointestinal tract differs between individuals but is improved if the drug is given with a high-fat meal. Griseofulvin appears in the stratum corneum within a few hours of ingestion, as a result of secretion in perspiration. However, levels begin to fall soon after the drug is discontinued, and within 48 to 72 h it can no longer be detected. Griseofulvin is metabolized by the liver to 6-desmethyl griseofulvin, which is excreted in the urine.</para>
        <anchor id="ch0155s0026s0003a0003"/>
        <beginpage pagenum="2628"/>
      </sect2>
      <sect2 id="ch0155s0026s0004">
        <title>Clinical Use</title>
        <anchor id="ch0155s0026s0004a0001"/>
        <anchor id="ch0155s0026s0004a0002"/>
        <para id="ch0155s0026s0004p0001">Newer oral agents, such as terbinafine or itraconazole, are often preferred for nail infections, but griseofulvin remains a useful second-line agent for moderate to severe dermatophytoses of the skin and scalp hair, where topical treatment is considered inappropriate or has failed. Neither the CLSI nor EUCAST has breakpoints for griseofulvin.</para>
      </sect2>
      <sect2 id="ch0155s0026s0005">
        <title>Drug Interactions</title>
        <anchor id="ch0155s0026s0005a0001"/>
        <anchor id="ch0155s0026s0005a0002"/>
        <para id="ch0155s0026s0005p0001">Absorption of griseofulvin is reduced in persons receiving concomitant treatment with barbiturates. Griseofulvin may decrease the effectiveness of oral anticoagulants, oral contraceptives, and cyclosporine.</para>
      </sect2>
      <sect2 id="ch0155s0026s0006">
        <title>Toxicity and Adverse Effects</title>
        <anchor id="ch0155s0026s0006a0001"/>
        <anchor id="ch0155s0026s0006a0002"/>
        <para id="ch0155s0026s0006p0001">In most cases, prolonged courses and high doses are well tolerated. Adverse effects occur in around 15% of patients, and include headache, nausea, vomiting and abdominal discomfort, and rashes.</para>
      </sect2>
      <sect2 id="ch0155s0026s0007">
        <title>NOVEL ANTIFUNGAL AGENTS IN DEVELOPMENT</title>
        <anchor id="ch0155s0026s0007a0001"/>
        <anchor id="ch0155s0026s0007a0002"/>
        <para id="ch0155s0026s0007p0001">We are currently in an era of growth for new antifungal agents. New antifungal compounds, including compounds with novel targets as well as promising improvements on existing antifungal drugs, are currently in development. Discussed below are those compounds that have reached at least phase II clinical trials.</para>
      </sect2>
    </sect1>
    <sect1 id="ch0155s0027">
      <title>Fosmanogepix</title>
      <anchor id="ch0155s0027a0001"/>
      <anchor id="ch0155s0027a0002"/>
      <para id="ch0155s0027p0001">Fosmanogepix is the prodrug of the active compound manogepix (APX001, E1210, Pfizer), a small molecule inhibitor of inositol acyltransferase, and blocks the maturation of some glycosylphosphatidylinositol-anchored mannoproteins. It is available as either oral or IV administration. Manogepix exhibits potent broad-spectrum antifungal activity against<emphasis>Candida</emphasis> spp. and <emphasis>Aspergillus</emphasis> spp., as well as other molds that are difficult to treat such as <emphasis>Fusarium</emphasis> spp., <emphasis>Scedosporium</emphasis> spp., and <emphasis>Lomentospora prolificans</emphasis> (<link linkend="ch0155s0033s0002li0156">156</link>, <link linkend="ch0155s0033s0002li0157">157</link>). It has no activity against <emphasis>C. krusei</emphasis>, and activity against the Mucorales is variable (<link linkend="ch0155s0033s0002li0157">157</link>). Manogepix is also active against fungal isolates which are azole and/or echinocandin resistant, including the emerging pathogen <emphasis>C. auris</emphasis> (<link linkend="ch0155s0033s0002li0147">147</link>, <link linkend="ch0155s0033s0002li0158">158</link>–<link linkend="ch0155s0033s0002li0160">160</link>). There are currently three ongoing phase II clinical trials with manogepix: treatment of invasive fungal disease caused by <emphasis>Aspergillus</emphasis> and rare molds, treatment of candidemia in nonneutropenic patients, and treatment of invasive disease caused by <emphasis>C. auris</emphasis> (<link linkend="ch0155s0033s0002li0141">141</link>, <link linkend="ch0155s0033s0002li0161">161</link>).</para>
    </sect1>
    <sect1 id="ch0155s0028">
      <title>Ibrexafungerp</title>
      <anchor id="ch0155s0028a0001"/>
      <anchor id="ch0155s0028a0002"/>
      <para id="ch0155s0028p0001">Ibrexafungerp (SCY-078, MK-3118, Scynexis) is a structurally distinct class of β-1,3-<emphasis role="smallcaps">D</emphasis>-glucan synthase inhibitor, a triterpene glucan synthase inhibitor, that has been developed to treat invasive and mucosal fungal infections. Unlike current echinocandins, it is orally bioavailable, and activity is not compromised by the most common mutations within the protein target Fks (<link linkend="ch0155s0033s0002li0162">162</link>–<link linkend="ch0155s0033s0002li0164">164</link>). Ibrexafungerp shows fungicidal activity against the most common <emphasis>Candida</emphasis> species, <emphasis>C. auris</emphasis>, as well as fungistatic activity against <emphasis>Aspergillus</emphasis> spp., <emphasis>Paecilomyces variotii</emphasis>, and <emphasis>Lomentospora prolificans</emphasis> (<link linkend="ch0155s0033s0002li0165">165</link>–<link linkend="ch0155s0033s0002li0167">167</link>). As would be expected, there is no activity against Mucorales or <emphasis>Fusarium</emphasis> spp. Ibrexafungerp has been approved by the U.S. Food and Drug Administration (FDA) for treatment of vulvovaginal candidiasis. Phase II studies targeting invasive candidiasis have been completed. Phase III trials have begun for treatment of invasive <emphasis>C. auris</emphasis> and a trial for treatment of invasive <emphasis>Candida</emphasis>, candidemia, and aspergillosis that are refractory to or intolerant of other treatment. A phase II combination trial with voriconazole for the treatment of invasive aspergillosis is also under way (<link linkend="ch0155s0033s0002li0141">141</link>, <link linkend="ch0155s0033s0002li0161">161</link>). An IV formulation is in development.</para>
    </sect1>
    <sect1 id="ch0155s0029">
      <title>Olorofim</title>
      <anchor id="ch0155s0029a0001"/>
      <anchor id="ch0155s0029a0002"/>
      <para id="ch0155s0029p0001">Olorofim (F901318, F2G Ltd.) is a member of a new class of orotomide antifungal agents that inhibit an enzyme involved in pyrimidine biosynthesis, dihydroorotate dehydrogenase (DHODH). It has been developed in both oral and intravenous formulations for the treatment of systemic mold infections. It shows potent activity against a broad range of filamentous and dimorphic fungi, including<emphasis>Aspergillus</emphasis> spp., <emphasis>Histoplasma capsulatum, Blastomyces dermatitidis, Coccidiodes immitis, Fusarium</emphasis> spp., <emphasis>Talaromyces marneffei, Scedosporium</emphasis> spp., and <emphasis>Lomentospora prolificans</emphasis> (<link linkend="ch0155s0033s0002li0168">168</link>–<link linkend="ch0155s0033s0002li0170">170</link>). Of note, this agent is effective against azole-resistant <emphasis>A. fumigatus</emphasis> harboring the TR<subscript>34</subscript>/L98H mutation both <emphasis>in vitro</emphasis> and <emphasis>in vivo</emphasis> (<link linkend="ch0155s0033s0002li0171">171</link>, <link linkend="ch0155s0033s0002li0172">172</link>). Little to no activity is seen against <emphasis>Candida</emphasis> spp. or the Mucorales (<link linkend="ch0155s0033s0002li0168">168</link>). Olorofim is in a phase II clinical trial for the treatment of resistant invasive fungal disease including infections caused by <emphasis>Scedosporium, Lomentospora</emphasis>, and azole-resistant <emphasis>Aspergillus</emphasis> (<link linkend="ch0155s0033s0002li0141">141</link>, <link linkend="ch0155s0033s0002li0161">161</link>).</para>
    </sect1>
    <sect1 id="ch0155s0030">
      <title>Rezafungin</title>
      <anchor id="ch0155s0030a0001"/>
      <anchor id="ch0155s0030a0002"/>
      <para id="ch0155s0030p0001">Rezafungin (CD101, Cidara Therapeutics) was developed to overcome the need for daily IV administration of an echinocandin while preserving the benefits of low toxicity and fungal-specific activity associated with this drug class. Adjustments to the echinocandin backbone chemical structure lowered the clearance of rezafungin and afforded a longer compound half-life, about 3-fold longer than that of anidulafungin (<link linkend="ch0155s0033s0002li0173">173</link>). Therefore, once-weekly intravenous administration provides appropriate systemic levels of rezafungin for treatment of invasive fungal infections (<link linkend="ch0155s0033s0002li0174">174</link>). This compound exhibits activity against echinocandin-resistant <emphasis>Candida</emphasis> spp., including <emphasis>C. auris</emphasis>, as well as <emphasis>Aspergillus</emphasis> spp. (<link linkend="ch0155s0033s0002li0175">175</link>, <link linkend="ch0155s0033s0002li0176">176</link>). A phase III trial against invasive candidiasis has been completed and an FDA determination is pending. A second trial for the prevention of invasive fungal disease by <emphasis>Candida, Aspergillus</emphasis>, or <emphasis>Pneumocystis jirovecii</emphasis> in patients undergoing allogeneic bone marrow transplants is ongoing (<link linkend="ch0155s0033s0002li0141">141</link>, <link linkend="ch0155s0033s0002li0161">161</link>).</para>
    </sect1>
    <sect1 id="ch0155s0031">
      <title>Oteseconazole and VT-1598</title>
      <anchor id="ch0155s0031a0001"/>
      <anchor id="ch0155s0031a0002"/>
      <para id="ch0155s0031p0001">Oteseconazole (VT-1161, Mycovia Pharmaceuticals, Inc.) and VT-1598 (Mycovia Pharmaceuticals, Inc.) were developed as fungal-specific lanosterol 14α-demethylase inhibitors in the tetrazole class that selectively target the fungal enzyme over the human enzyme and result in fewer drug-drug interactions (<link linkend="ch0155s0033s0002li0177">177</link>). Oteseconazole shows potent <emphasis>in vitro</emphasis> and <emphasis>in vivo</emphasis> activity against <emphasis>Candida</emphasis> spp., <emphasis>Coccidioides</emphasis> spp., and <emphasis>Trichophyton</emphasis> spp. but is not active against <emphasis>Aspergillus</emphasis> spp. as monotherapy (<link linkend="ch0155s0033s0002li0178">178</link>–<link linkend="ch0155s0033s0002li0181">181</link>). Phase III clinical trials for the treatment of acute and recurrent vulvovaginal candidiasis have been completed and FDA approval is pending. A phase II clinical trial for toenail onychomycosis has been completed (<link linkend="ch0155s0033s0002li0141">141</link>, <link linkend="ch0155s0033s0002li0161">161</link>). VT-1598 displays an even broader antifungal range; it shows <emphasis>in vitro</emphasis> activity against <emphasis>Candida</emphasis> spp. including <emphasis>C. auris, Cryptococcus</emphasis> spp., <emphasis>Aspergillus</emphasis> spp., <emphasis>Rhizopus arrhizus, Blastomyces dermatitidis, Coccidioides</emphasis> spp., and <emphasis>Histoplasma capsulatum</emphasis> (<link linkend="ch0155s0033s0002li0182">182</link>–<link linkend="ch0155s0033s0002li0184">184</link>). Phase I clinical safety trials are ongoing.</para>
      <anchor id="ch0155s0031a0003"/>
      <beginpage pagenum="2629"/>
    </sect1>
    <sect1 id="ch0155s0032">
      <title>Albaconazole</title>
      <anchor id="ch0155s0032a0001"/>
      <anchor id="ch0155s0032a0002"/>
      <para id="ch0155s0032p0001">Albaconazole (Stiefel, a GlaxoSmithKline Company) is an oral triazole agent that has demonstrated high levels of bioavailability and antifungal activity. It was evaluated in a phase I trial for tinea pedis and has completed a phase II trial for the treatment of toenail onychomycosis (<link linkend="ch0155s0033s0002li0185">185</link>–<link linkend="ch0155s0033s0002li0187">187</link>).</para>
    </sect1>
    <sect1 id="ch0155s0033">
      <title>Opelconazole</title>
      <anchor id="ch0155s0033a0001"/>
      <anchor id="ch0155s0033a0002"/>
      <para id="ch0155s0033p0001">Opelconazole (PC945, Pulmocide) is a triazole antifungal that is being specifically developed for aerosolized delivery directly to the lungs through the use of a nebulizer (<link linkend="ch0155s0033s0002li0188">188</link>). It has activity against <emphasis>A. fumigatus</emphasis>, including some azole-resistant isolates, and <emphasis>A. terreus</emphasis>, but poor <emphasis>in vitro</emphasis> activity against <emphasis>A. flavus</emphasis> and <emphasis>A. niger.</emphasis> Activity against Mucorales was poor, with the possible exception of <emphasis>Rhizopus arrhizus</emphasis> (<link linkend="ch0155s0033s0002li0189">189</link>). A phase III clinical trial is set to begin for adults with invasive pulmonary aspergillosis and limited or no alternative treatment options; the study will be a combined treatment regimen (<link linkend="ch0155s0033s0002li0141">141</link>, <link linkend="ch0155s0033s0002li0161">161</link>).</para>
      <sect2 id="ch0155s0033s0001">
        <title>CONCLUSION</title>
        <anchor id="ch0155s0033s0001a0001"/>
        <anchor id="ch0155s0033s0001a0002"/>
        <para id="ch0155s0033s0001p0001">The recent surge in development of new antifungal agents will greatly increase the number of compounds available to combat the growing number of serious fungal infections. There are now few life-threatening conditions for which there is no effective treatment, and there are many for which there are several therapeutic options. However, we are seeing the emergence of multidrug-resistant yeasts, including<emphasis>C. glabrata</emphasis> and <emphasis>C. auris</emphasis>, and azole-resistant <emphasis>A. fumigatus</emphasis>, so effective antifungal stewardship will be a challenge. With judicious use of the available agents, antifungal drug resistance can be mitigated. It remains to be seen which, if any, of the new antifungal agents in development will reach the marketplace.</para>
        <para id="ch0155s0033s0001p0002"><emphasis>The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention</emphasis>.</para>
      </sect2>
      <sect2 id="ch0155s0033s0002">
        <title>REFERENCES</title>
        <anchor id="ch0155s0033s0002a0001"/>
        <anchor id="ch0155s0033s0002a0002"/>
        <itemizedlist mark="none" role="biblioEntryList">
          <listitem id="ch0155s0033s0002li0001" role="bibliographyEntry">
            <para>1.<emphasis role="strong">Ryder NS.</emphasis> 1991. Squalene epoxidase as a target for the allylamines. <citetitle><emphasis>Biochem Soc Trans</emphasis></citetitle> <emphasis role="strong">19:</emphasis>774–777.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0002" role="bibliographyEntry">
            <para>2.<emphasis role="strong">Favre B, Hofbauer B, Hildering KS, Ryder NS.</emphasis> 2003. Comparison of in vitro activities of 17 antifungal drugs against a panel of 20 dermatophytes by using a microdilution assay. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">41:</emphasis>4817–4819.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0003" role="bibliographyEntry">
            <para>3.<emphasis role="strong">Fernández-Torres B, Carrillo AJ, Martín E, Del Palacio A, Moore MK, Valverde A, Serrano M, Guarro J.</emphasis> 2001. In vitro activities of 10 antifungal drugs against 508 dermatophyte strains. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">45:</emphasis>2524–2528.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0004" role="bibliographyEntry">
            <para>4.<emphasis role="strong">Perea S, Fothergill AW, Sutton DA, Rinaldi MG.</emphasis> 2001. Comparison of in vitro activities of voriconazole and five established antifungal agents against different species of dermatophytes using a broth macrodilution method. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">39:</emphasis>385–388.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0005" role="bibliographyEntry">
            <para>5.<emphasis role="strong">McGinnis MR, Pasarell L.</emphasis> 1998. In vitro evaluation of terbinafine and itraconazole against dematiaceous fungi. <citetitle><emphasis>Med Mycol</emphasis></citetitle> <emphasis role="strong">36:</emphasis>243–246.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0006" role="bibliographyEntry">
            <para>6.<emphasis role="strong">Schmitt HJ, Bernard EM, Andrade J, Edwards F, Schmitt B, Armstrong D.</emphasis> 1988. MIC and fungicidal activity of terbinafine against clinical isolates of <citetitle><emphasis>Aspergillus</emphasis></citetitle> spp. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">32:</emphasis>780–781.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0007" role="bibliographyEntry">
            <para>7.<emphasis role="strong">Ryder NS, Wagner S, Leitner I.</emphasis> 1998. In vitro activities of terbinafine against cutaneous isolates of <citetitle><emphasis>Candida albicans</emphasis></citetitle> and other pathogenic yeasts. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">42:</emphasis>1057–1061.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0008" role="bibliographyEntry">
            <para>8.<emphasis role="strong">Shadomy S, Espinel-Ingroff A, Gebhart RJ.</emphasis> 1985. In-vitro studies with SF 86-327, a new orally active allylamine derivative. <citetitle><emphasis>Sabouraudia</emphasis></citetitle> <emphasis role="strong">23:</emphasis>125–132.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0009" role="bibliographyEntry">
            <para>9.<emphasis role="strong">Hahn RC, Fontes CJ, Batista RD, Hamdan JS.</emphasis> 2002. In vitro comparison of activities of terbinafine and itraconazole against <citetitle><emphasis>Paracoccidioides brasiliensis. J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">40:</emphasis>2828–2831.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0010" role="bibliographyEntry">
            <para>10.<emphasis role="strong">McGinnis MR, Nordoff NG, Ryder NS, Nunn GB.</emphasis> 2000. In vitro comparison of terbinafine and itraconazole against <citetitle><emphasis>Penicillium marneffei. Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">44:</emphasis>1407–1408.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0011" role="bibliographyEntry">
            <para>11.<emphasis role="strong">Rudramurthy SM, Shankarnarayan SA, Dogra S, Shaw D, Mushtaq K, Paul RA, Narang T, Chakrabarti A.</emphasis> 2018. Mutation in the squalene epoxidase gene of <citetitle><emphasis>Trichophyton interdigitale</emphasis></citetitle> and <citetitle><emphasis>Trichophyton rubrum</emphasis></citetitle> associated with allylamine resistance. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">62:</emphasis>e02522–17.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0012" role="bibliographyEntry">
            <para>12.<emphasis role="strong">Singh A, Masih A, Khurana A, Singh PK, Gupta M, Hagen F, Meis JF, Chowdhary A.</emphasis> 2018. High terbinafine resistance in <citetitle><emphasis>Trichophyton interdigitale</emphasis></citetitle> isolates in Delhi, India harbouring mutations in the squalene epoxidase gene. <citetitle><emphasis>Mycoses</emphasis></citetitle> <emphasis role="strong">61:</emphasis>477–484.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0013" role="bibliographyEntry">
            <para>13.<emphasis role="strong">Singh A, Masih A, Monroy-Nieto J, Singh PK, Bowers J, Travis J, Khurana A, Engelthaler DM, Meis JF, Chowdhary A.</emphasis> 2019. A unique multidrug-resistant clonal <citetitle><emphasis>Trichophyton</emphasis></citetitle> population distinct from <citetitle><emphasis>Trichophyton mentagrophytes</emphasis></citetitle>/<citetitle><emphasis>Trichophyton interdigitale</emphasis></citetitle> complex causing an ongoing alarming dermatophytosis outbreak in India: genomic insights and resistance profile. <citetitle><emphasis>Fungal Genet Biol</emphasis></citetitle> <emphasis role="strong">133:</emphasis>103266.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0014" role="bibliographyEntry">
            <para>14.<emphasis role="strong">Kano R, Kimura U, Kakurai M, Hiruma J, Kamata H, Suga Y, Harada K.</emphasis> 2020. <citetitle><emphasis>Trichophyton indotineae</emphasis></citetitle> sp. nov.: a new highly terbinafine-resistant anthropophilic dermatophyte species. <citetitle><emphasis>Mycopathologia</emphasis></citetitle> <emphasis role="strong">185:</emphasis>947–958.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0015" role="bibliographyEntry">
            <para>15.<emphasis role="strong">Tang C, Kong X, Ahmed SA, Thakur R, Chowdhary A, Nenoff P, Uhrlass S, Verma SB, Meis JF, Kandemir H, Kang Y, de Hoog GS.</emphasis> 2021. Taxonomy of the <citetitle><emphasis>Trichophyton mentagrophytes/T. interdigitale</emphasis></citetitle> species complex harboring the highly virulent, multiresistant genotype <citetitle><emphasis>T. indotineae. Mycopathologia</emphasis></citetitle> <emphasis role="strong">186:</emphasis>315–326.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0016" role="bibliographyEntry">
            <para>16.<emphasis role="strong">Astvad KMT, Hare RK, Jørgensen KM, Saunte DML, Thomsen PK, Arendrup MC.</emphasis> 2022. Increasing terbinafine resistance in Danish <citetitle><emphasis>Trichophyton</emphasis></citetitle> isolates 2019-2020. <citetitle><emphasis>J Fungi (Basel)</emphasis></citetitle> <emphasis role="strong">8:</emphasis>150.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0017" role="bibliographyEntry">
            <para>17.<emphasis role="strong">Jabet A, Brun S, Normand AC, Imbert S, Akhoundi M, Dannaoui E, Audiffred L, Chasset F, Izri A, Laroche L, Piarroux R, Bachmeyer C, Hennequin C, Sabater AM.</emphasis> 2022. Extensive dermatophytosis caused by terbinafine-resistant <citetitle><emphasis>Trichophyton indotineae</emphasis></citetitle>, France. <citetitle><emphasis>Emerg Infect Dis</emphasis></citetitle> <emphasis role="strong">28:</emphasis>229–233.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0018" role="bibliographyEntry">
            <para>18.<emphasis role="strong">Posso-De Los Rios CJ, Tadros E, Summerbell RC, Scott JA.</emphasis> 2022. Terbinafine resistant <citetitle><emphasis>Trichophyton indotineae</emphasis></citetitle> isolated in patients with superficial dermatophyte infection in Canadian patients. <citetitle><emphasis>J Cutan Med Surg</emphasis></citetitle> <emphasis role="strong">26:</emphasis>371–376.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0019" role="bibliographyEntry">
            <para>19.<emphasis role="strong">Kovarik JM, Mueller EA, Zehender H, Denouël J, Caplain H, Millerioux L.</emphasis> 1995. Multiple-dose pharmacokinetics and distribution in tissue of terbinafine and metabolites. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">39:</emphasis>2738–2741.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0020" role="bibliographyEntry">
            <para>20.<emphasis role="strong">Vickers AE, Sinclair JR, Zollinger M, Heitz F, Glänzel U, Johanson L, Fischer V.</emphasis> 1999. Multiple cytochrome P-450s involved in the metabolism of terbinafine suggest a limited potential for drug-drug interactions. <citetitle><emphasis>Drug Metab Dispos</emphasis></citetitle> <emphasis role="strong">27:</emphasis>1029–1038.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0021" role="bibliographyEntry">
            <para>21.<emphasis role="strong">Darkes MJ, Scott LJ, Goa KL.</emphasis> 2003. Terbinafine: a review of its use in onychomycosis in adults. <citetitle><emphasis>Am J Clin Dermatol</emphasis></citetitle> <emphasis role="strong">4:</emphasis>39–65.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0022" role="bibliographyEntry">
            <para>22.<emphasis role="strong">Krishnan-Natesan S.</emphasis> 2009. Terbinafine: a pharmacological and clinical review. <citetitle><emphasis>Expert Opin Pharmacother</emphasis></citetitle> <emphasis role="strong">10:</emphasis>2723–2733.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0023" role="bibliographyEntry">
            <para>23.<emphasis role="strong">Revankar SG, Nailor MD, Sobel JD.</emphasis> 2008. Use of terbinafine in rare and refractory mycoses. <citetitle><emphasis>Future Microbiol</emphasis></citetitle> <emphasis role="strong">3:</emphasis>9–17.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0024" role="bibliographyEntry">
            <anchor id="ch0155s0033s0002a0003"/>
            <para>24.<emphasis role="strong">Howden BP, Slavin MA, Schwarer AP, Mijch AM.</emphasis> 2003. Successful control of disseminated <citetitle><emphasis>Scedosporium prolificans</emphasis></citetitle> infection with a combination of voriconazole and terbinafine. <citetitle><emphasis>Eur J Clin Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">22:</emphasis>111–113.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0025" role="bibliographyEntry">
            <para>25.<emphasis role="strong">Bhat SV, Paterson DL, Rinaldi MG, Veldkamp PJ.</emphasis> 2007. <citetitle><emphasis>Scedosporium prolificans</emphasis></citetitle> brain abscess in a patient with chronic granulomatous disease: successful combination therapy with voriconazole and terbinafine. <citetitle><emphasis>Scand J Infect Dis</emphasis></citetitle> <emphasis role="strong">39:</emphasis>87–90.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0026" role="bibliographyEntry">
            <para>26.<emphasis role="strong">Hall M, Monka C, Krupp P, O’Sullivan D.</emphasis> 1997. Safety of oral terbinafine: results of a postmarketing surveillance study in 25,884 patients. <citetitle><emphasis>Arch Dermatol</emphasis></citetitle> <emphasis role="strong">133:</emphasis>1213–1219.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0027" role="bibliographyEntry">
            <para>27.<emphasis role="strong">Manavathu EK, Cutright JL, Chandrasekar PH.</emphasis> 1998. Organism-dependent fungicidal activities of azoles. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">42:</emphasis>3018–3021.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0028" role="bibliographyEntry">
            <para>28.<emphasis role="strong">Berkow EL, Lockhart SR.</emphasis> 2017. Fluconazole resistance in <citetitle><emphasis>Candida</emphasis></citetitle> species: a current perspective. <citetitle><emphasis>Infect Drug Resist</emphasis></citetitle> <emphasis role="strong">10:</emphasis>237–245.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0029" role="bibliographyEntry">
            <para>29.<emphasis role="strong">Chowdhary A, Sharma C, Hagen F, Meis JF.</emphasis> 2014. Exploring azole antifungal drug resistance in <citetitle><emphasis>Aspergillus fumigatus</emphasis></citetitle> with special reference to resistance mechanisms. <citetitle><emphasis>Future Microbiol</emphasis></citetitle> <emphasis role="strong">9:</emphasis>697–711.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0030" role="bibliographyEntry">
            <para>30.<emphasis role="strong">Heykants J, Van Peer A, Van de Velde V, Van Rooy P, Meuldermans W, Lavrijsen K, Woestenborghs R, Van Cutsem J, Cauwenbergh G.</emphasis> 1989. The clinical pharmacokinetics of itraconazole: an overview. <citetitle><emphasis>Mycoses</emphasis></citetitle> <emphasis role="strong">32</emphasis>(Suppl 1)<emphasis role="strong">:</emphasis>67–87.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0031" role="bibliographyEntry">
            <para>31.<emphasis role="strong">Ezzet F, Wexler D, Courtney R, Krishna G, Lim J, Laughlin M.</emphasis> 2005. Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations. <citetitle><emphasis>Clin Pharmacokinet</emphasis></citetitle> <emphasis role="strong">44:</emphasis>211–220.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0032" role="bibliographyEntry">
            <para>32.<emphasis role="strong">Purkins L, Wood N, Kleinermans D, Greenhalgh K, Nichols D.</emphasis> 2003. Effect of food on the pharmacokinetics of multiple-dose oral voriconazole. <citetitle><emphasis>Br J Clin Pharmacol</emphasis></citetitle> <emphasis role="strong">56</emphasis>(Suppl 1)<emphasis role="strong">:</emphasis>17–23.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0033" role="bibliographyEntry">
            <para>33.<emphasis role="strong">Lipp HP.</emphasis> 2011. Posaconazole: clinical pharmacokinetics and drug interactions. <citetitle><emphasis>Mycoses</emphasis></citetitle> <emphasis role="strong">54</emphasis>(Suppl 1)<emphasis role="strong">:</emphasis>32–38.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0034" role="bibliographyEntry">
            <para>34.<emphasis role="strong">Lestner J, Hope WW.</emphasis> 2013. Itraconazole: an update on pharmacology and clinical use for treatment of invasive and allergic fungal infections. <citetitle><emphasis>Expert Opin Drug Metab Toxicol</emphasis></citetitle> <emphasis role="strong">9:</emphasis>911–926.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0035" role="bibliographyEntry">
            <para>35.<emphasis role="strong">Bellmann R, Smuszkiewicz P.</emphasis> 2017. Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients. <citetitle><emphasis>Infection</emphasis></citetitle> <emphasis role="strong">45:</emphasis>737–779.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0036" role="bibliographyEntry">
            <para>36.<emphasis role="strong">Walsh TJ, Karlsson MO, Driscoll T, Arguedas AG, Adamson P, Saez-Llorens X, Vora AJ, Arrieta AC, Blumer J, Lutsar I, Milligan P, Wood N.</emphasis> 2004. Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">48:</emphasis>2166–2172.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0037" role="bibliographyEntry">
            <para>37.<emphasis role="strong">Theuretzbacher U, Ihle F, Derendorf H.</emphasis> 2006. Pharmacokinetic/pharmacodynamic profile of voriconazole. <citetitle><emphasis>Clin Pharmacokinet</emphasis></citetitle> <emphasis role="strong">45:</emphasis>649–663.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0038" role="bibliographyEntry">
            <para>38.<emphasis role="strong">Riddell J IV, Comer GM, Kauffman CA.</emphasis> 2011. Treatment of endogenous fungal endophthalmitis: focus on new antifungal agents. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">52:</emphasis>648–653.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0039" role="bibliographyEntry">
            <para>39.<emphasis role="strong">Cauwenbergh G, Degreef H, Heykants J, Woestenborghs R, Van Rooy P, Haeverans K.</emphasis> 1988. Pharmacokinetic profile of orally administered itraconazole in human skin. <citetitle><emphasis>J Am Acad Dermatol</emphasis></citetitle> <emphasis role="strong">18:</emphasis>263–268.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0040" role="bibliographyEntry">
            <para>40.<emphasis role="strong">Thomas L, Tracy CR.</emphasis> 2015. Treatment of fungal urinary tract infection. <citetitle><emphasis>Urol Clin North Am</emphasis></citetitle> <emphasis role="strong">42:</emphasis>473–483.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0041" role="bibliographyEntry">
            <para>41.<emphasis role="strong">Krieter P, Flannery B, Musick T, Gohdes M, Martinho M, Courtney R.</emphasis> 2004. Disposition of posaconazole following single-dose oral administration in healthy subjects. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">48:</emphasis>3543–3551.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0042" role="bibliographyEntry">
            <para>42.<emphasis role="strong">Odds FC, Bossche HV.</emphasis> 2000. Antifungal activity of itraconazole compared with hydroxy-itraconazole in vitro. <citetitle><emphasis>J Antimicrob Chemother</emphasis></citetitle> <emphasis role="strong">45:</emphasis>371–373.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0043" role="bibliographyEntry">
            <para>43.<emphasis role="strong">Li X, Yu C, Wang T, Chen K, Zhai S, Tang H.</emphasis> 2016. Effect of cytochrome P450 2C19 polymorphisms on the clinical outcomes of voriconazole: a systematic review and meta-analysis. <citetitle><emphasis>Eur J Clin Pharmacol</emphasis></citetitle> <emphasis role="strong">72:</emphasis>1185–1193.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0044" role="bibliographyEntry">
            <para>44.<emphasis role="strong">Kovanda LL, Maher R, Hope WW.</emphasis> 2016. Isavuconazonium sulfate: a new agent for the treatment of invasive aspergillosis and invasive mucormycosis. <citetitle><emphasis>Expert Rev Clin Pharmacol</emphasis></citetitle> <emphasis role="strong">9:</emphasis>887–897.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0045" role="bibliographyEntry">
            <para>45.<emphasis role="strong">Gubbins PO.</emphasis> 2011. Triazole antifungal agents drug-drug interactions involving hepatic cytochrome P450. <citetitle><emphasis>Expert Opin Drug Metab Toxicol</emphasis></citetitle> <emphasis role="strong">7:</emphasis>1411–1429.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0046" role="bibliographyEntry">
            <para>46.<emphasis role="strong">Pfaller MA, Diekema DJ, Gibbs DL, Newell VA, Ellis D, Tullio V, Rodloff A, Fu W, Ling TA, Global Antifungal Surveillance Group.</emphasis> 2010. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-year analysis of susceptibilities of <citetitle><emphasis>Candida</emphasis></citetitle> species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">48:</emphasis>1366–1377.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0047" role="bibliographyEntry">
            <para>47.<emphasis role="strong">Espinel-Ingroff A, Chowdhary A, Cuenca-Estrella M, Fothergill A, Fuller J, Hagen F, Govender N, Guarro J, Johnson E, Lass-Flörl C, Lockhart SR, Martins MA, Meis JF, Melhem MS, Ostrosky-Zeichner L, Pelaez T, Pfaller MA, Schell WA, Trilles L, Kidd S, Turnidge J.</emphasis> 2012. <citetitle><emphasis>Cryptococcus neoformans-Cryptococcus gattii</emphasis></citetitle> species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for amphotericin B and flucytosine. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">56:</emphasis>3107–3113.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0048" role="bibliographyEntry">
            <para>48.<emphasis role="strong">Pfaller MA, Messer SA, Hollis RJ, Boyken L, Tendolkar S, Kroeger J, Diekema DJ.</emphasis> 2009. Variation in susceptibility of bloodstream isolates of <citetitle><emphasis>Candida glabrata</emphasis></citetitle> to fluconazole according to patient age and geographic location in the United States in 2001 to 2007. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">47:</emphasis>3185–3190.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0049" role="bibliographyEntry">
            <para>49.<emphasis role="strong">González GM, Fothergill AW, Sutton DA, Rinaldi MG, Loebenberg D.</emphasis> 2005. In vitro activities of new and established triazoles against opportunistic filamentous and dimorphic fungi. <citetitle><emphasis>Med Mycol</emphasis></citetitle> <emphasis role="strong">43:</emphasis>281–284.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0050" role="bibliographyEntry">
            <para>50.<emphasis role="strong">Sanglard D, Odds FC.</emphasis> 2002. Resistance of <citetitle><emphasis>Candida</emphasis></citetitle> species to antifungal agents: molecular mechanisms and clinical consequences. <citetitle><emphasis>Lancet Infect Dis</emphasis></citetitle> <emphasis role="strong">2:</emphasis>73–85.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0051" role="bibliographyEntry">
            <para>51.<emphasis role="strong">Lockhart SR, Etienne KA, Vallabhaneni S, Farooqi J, Chowdhary A, Govender NP, Colombo AL, Calvo B, Cuomo CA, Desjardins CA, Berkow EL, Castanheira M, Magobo RE, Jabeen K, Asghar RJ, Meis JF, Jackson B, Chiller T, Litvintseva AP.</emphasis> 2017. Simultaneous emergence of multidrug-resistant <citetitle><emphasis>Candida auris</emphasis></citetitle> on 3 continents confirmed by whole-genome sequencing and epidemiological analyses. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">64:</emphasis>134–140.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0052" role="bibliographyEntry">
            <para>52.<emphasis role="strong">Govender NP, Patel J, van Wyk M, Chiller TM, Lockhart SR, Group for Enteric, Respiratory and Meningeal Disease Surveillance in South Africa (GERMS-SA).</emphasis> 2011. Trends in antifungal drug susceptibility of <citetitle><emphasis>Cryptococcus neoformans</emphasis></citetitle> isolates obtained through population-based surveillance in South Africa in 2002–2003 and 2007–2008. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">55:</emphasis>2606–2611.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0053" role="bibliographyEntry">
            <para>53.<emphasis role="strong">Castanheira M, Deshpande LM, Messer SA, Rhomberg PR, Pfaller MA.</emphasis> 2020. Analysis of global antifungal surveillance results reveals predominance of Erg11 Y132F alteration among azole-resistant <citetitle><emphasis>Candida parapsilosis</emphasis></citetitle> and <citetitle><emphasis>Candida tropicalis</emphasis></citetitle> and country-specific isolate dissemination. <citetitle><emphasis>Int J Antimicrob Agents</emphasis></citetitle> <emphasis role="strong">55:</emphasis>105799.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0054" role="bibliographyEntry">
            <para>54.<emphasis role="strong">Alcoceba E, Gómez A, Lara-Esbrí P, Oliver A, Beltrán AF, Ayestarán I, Muñoz P, Escribano P, Guinea J.</emphasis> 2022. Fluconazole-resistant <citetitle><emphasis>Candida parapsilosis</emphasis></citetitle> clonally related genotypes: first report proving the presence of endemic isolates harbouring the Y132F ERG11 gene substitution in Spain. <citetitle><emphasis>Clin Microbiol Infect</emphasis></citetitle> <emphasis role="strong">28:</emphasis>1113–1119.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0055" role="bibliographyEntry">
            <para>55.<emphasis role="strong">Thomaz DY, de Almeida JN Jr, Sejas ONE, Del Negro GMB, Carvalho GOMH, Gimenes VMF, de Souza MEB, Arastehfar A, Camargo CH, Motta AL, Rossi F, Perlin DS, Freire MP, Abdala E, Benard G.</emphasis> 2021. Environmental clonal spread of azole-resistant <citetitle><emphasis>Candida parapsilosis</emphasis></citetitle> with Erg11-Y132F mutation causing a large candidemia outbreak in a Brazilian cancer referral center. <citetitle><emphasis>J Fungi (Basel)</emphasis></citetitle> <emphasis role="strong">7:</emphasis>259.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0056" role="bibliographyEntry">
            <anchor id="ch0155s0033s0002a0004"/>
            <para>56.<emphasis role="strong">Magobo RE, Lockhart SR, Govender NP, Wadula J, Rensburg, van Rensburg CJ, Whitelaw A, Zietsman I, Miller N, Smith P, van Greune J, Brink A, Hoosen A, Perovic O, Nchabaleng M, Orth H, Coovadia Y, Badenhorst L, Moolman J, Peer AK, Govind C, Kularatne R, Bhagoobhai B, Prinsloo B, Haffejee S, Simpson J, Hoyland G, van Schalkwyk M, Bowie G, Hanise P, Vasaikar S, Wende L, Chiller T, Ahlquist-Cleveland A, Patel J.</emphasis> 2020. Fluconazole-resistant <citetitle><emphasis>Candida parapsilosis</emphasis></citetitle> strains with a Y132F substitution in the ERG11 gene causing invasive infections in a neonatal unit, South Africa. <citetitle><emphasis>Mycoses</emphasis></citetitle> <emphasis role="strong">63:</emphasis>471–477.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0057" role="bibliographyEntry">
            <para>57.<emphasis role="strong">Wang Y, Fan X, Wang H, Kudinha T, Mei YN, Ni F, Pan YH, Gao LM, Xu H, Kong HS, Yang Q, Wang WP, Xi HY, Luo YP, Ye LY, Xiao M, China Hospital Invasive Fungal Surveillance Net (CHIF-NET) Study Group.</emphasis> 2021. Continual decline in azole susceptibility rates in <citetitle><emphasis>Candida tropicalis</emphasis></citetitle> over a 9-year period in China. <citetitle><emphasis>Front Microbiol</emphasis></citetitle> <emphasis role="strong">12:</emphasis>702839.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0058" role="bibliographyEntry">
            <para>58.<emphasis role="strong">Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, Reboli AC, Schuster MG, Vazquez JA, Walsh TJ, Zaoutis TE, Sobel JD.</emphasis> 2016. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">62:</emphasis>e1–e50.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0059" role="bibliographyEntry">
            <para>59.<emphasis role="strong">Hartmann CA, Aye WT, Blair JE.</emphasis> 2016. Treatment considerations in pulmonary coccidioidomycosis. <citetitle><emphasis>Expert Rev Respir Med</emphasis></citetitle> <emphasis role="strong">10:</emphasis>1079–1091.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0060" role="bibliographyEntry">
            <para>60.<emphasis role="strong">Perfect JR, Dismukes WE, Dromer F, Goldman DL, Graybill JR, Hamill RJ, Harrison TS, Larsen RA, Lortholary O, Nguyen MH, Pappas PG, Powderly WG, Singh N, Sobel JD, Sorrell TC.</emphasis> 2010. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">50:</emphasis>291–322.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0061" role="bibliographyEntry">
            <para>61.<emphasis role="strong">Kauffman CA, Bustamante B, Chapman SW, Pappas PG, Infectious Diseases Society of America.</emphasis> 2007. Clinical practice guidelines for the management of sporotrichosis: 2007 update by the Infectious Diseases Society of America. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">45:</emphasis>1255–1265.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0062" role="bibliographyEntry">
            <para>62.<emphasis role="strong">Wheat LJ, Freifeld AG, Kleiman MB, Baddley JW, McKinsey DS, Loyd JE, Kauffman CA, Infectious Diseases Society of America.</emphasis> 2007. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">45:</emphasis>807–825.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0063" role="bibliographyEntry">
            <para>63.<emphasis role="strong">Andes D, Pascual A, Marchetti O.</emphasis> 2009. Antifungal therapeutic drug monitoring: established and emerging indications. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">53:</emphasis>24–34.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0064" role="bibliographyEntry">
            <para>64.<emphasis role="strong">Schmitt-Hoffmann A, Roos B, Maares J, Heep M, Spickerman J, Weidekamm E, Brown T, Roehrle M.</emphasis> 2006. Multiple-dose pharmacokinetics and safety of the new antifungal triazole BAL4815 after intravenous infusion and oral administration of its prodrug, BAL8557, in healthy volunteers. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">50:</emphasis>286–293.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0065" role="bibliographyEntry">
            <para>65.<emphasis role="strong">Schmitt-Hoffmann AH, Kato K, Townsend R, Potchoiba MJ, Hope WW, Andes D, Spickermann J, Schneidkraut MJ.</emphasis> 2017. Tissue distribution and elimination of isavuconazole following single and repeat oral-dose administration of isavuconazonium sulfate to rats. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">61:</emphasis>e01292–7.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0066" role="bibliographyEntry">
            <para>66.<emphasis role="strong">Astvad KMT, Hare RK, Arendrup MC.</emphasis> 2017. Evaluation of the in vitro activity of isavuconazole and comparator voriconazole against 2635 contemporary clinical <citetitle><emphasis>Candida</emphasis></citetitle> and <citetitle><emphasis>Aspergillus</emphasis></citetitle> isolates. <citetitle><emphasis>Clin Microbiol Infect</emphasis></citetitle> <emphasis role="strong">23:</emphasis>882–887.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0067" role="bibliographyEntry">
            <para>67.<emphasis role="strong">Hagen F, Illnait-Zaragozi MT, Bartlett KH, Swinne D, Geertsen E, Klaassen CH, Boekhout T, Meis JF.</emphasis> 2010. In vitro antifungal susceptibilities and amplified fragment length polymorphism genotyping of a worldwide collection of 350 clinical, veterinary, and environmental <citetitle><emphasis>Cryptococcus gattii</emphasis></citetitle> isolates. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">54:</emphasis>5139–5145.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0068" role="bibliographyEntry">
            <para>68.<emphasis role="strong">Thompson GR III, Wiederhold NP, Sutton DA, Fothergill A, Patterson TF.</emphasis> 2009. In vitro activity of isavuconazole against <citetitle><emphasis>Trichosporon, Rhodotorula, Geotrichum, Saccharomyces</emphasis></citetitle> and <citetitle><emphasis>Pichia</emphasis></citetitle> species. <citetitle><emphasis>J Antimicrob Chemother</emphasis></citetitle> <emphasis role="strong">64:</emphasis>79–83.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0069" role="bibliographyEntry">
            <para>69.<emphasis role="strong">Maertens JA, Raad II, Marr KA, Patterson TF, Kontoyiannis DP, Cornely OA, Bow EJ, Rahav G, Neofytos D, Aoun M, Baddley JW, Giladi M, Heinz WJ, Herbrecht R, Hope W, Karthaus M, Lee DG, Lortholary O, Morrison VA, Oren I, Selleslag D, Shoham S, Thompson GR III, Lee M, Maher RM, Schmitt-Hoffmann AH, Zeiher B, Ullmann AJ.</emphasis> 2016. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by <citetitle><emphasis>Aspergillus</emphasis></citetitle> and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. <citetitle><emphasis>Lancet</emphasis></citetitle> <emphasis role="strong">387:</emphasis>760–769.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0070" role="bibliographyEntry">
            <para>70.<emphasis role="strong">González GM.</emphasis> 2009. In vitro activities of isavuconazole against opportunistic filamentous and dimorphic fungi. <citetitle><emphasis>Med Mycol</emphasis></citetitle> <emphasis role="strong">47:</emphasis>71–76.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0071" role="bibliographyEntry">
            <para>71.<emphasis role="strong">Thompson GR III, Rendon A, Ribeiro Dos Santos R, Queiroz-Telles F, Ostrosky-Zeichner L, Azie N, Maher R, Lee M, Kovanda L, Engelhardt M, Vazquez JA, Cornely OA, Perfect JR.</emphasis> 2016. Isavuconazole treatment of cryptococcosis and dimorphic mycoses. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">63:</emphasis>356–362.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0072" role="bibliographyEntry">
            <para>72.<emphasis role="strong">Najafzadeh MJ, Badali H, Illnait-Zaragozi MT, De Hoog GS, Meis JF.</emphasis> 2010. In vitro activities of eight antifungal drugs against 55 clinical isolates of <citetitle><emphasis>Fonsecaea</emphasis></citetitle> spp. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">54:</emphasis>1636–1638.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0073" role="bibliographyEntry">
            <para>73.<emphasis role="strong">Feng P, Najafzadeh MJ, Sun J, Ahmed S, Xi L, de Hoog GS, Lai W, Lu C, Klaassen CH, Meis JF.</emphasis> 2012. In vitro activities of nine antifungal drugs against 81 <citetitle><emphasis>Phialophora</emphasis></citetitle> and <citetitle><emphasis>Cyphellophora</emphasis></citetitle> isolates. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">56:</emphasis>6044–6047.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0074" role="bibliographyEntry">
            <para>74.<emphasis role="strong">Arendrup MC, Jensen RH, Meletiadis J.</emphasis> 2015. In vitro activity of isavuconazole and comparators against clinical isolates of the Mucorales order. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">59:</emphasis>7735–7742.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0075" role="bibliographyEntry">
            <para>75.<emphasis role="strong">Verweij PE, González GM, Wiedrhold NP, Lass-Flörl C, Warn P, Heep M, Ghannoum MA, Guinea J.</emphasis> 2009. In vitro antifungal activity of isavuconazole against 345 mucorales isolates collected at study centers in eight countries. <citetitle><emphasis>J Chemother</emphasis></citetitle> <emphasis role="strong">21:</emphasis>272–281.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0076" role="bibliographyEntry">
            <para>76.<emphasis role="strong">Lackner M, de Hoog GS, Verweij PE, Najafzadeh MJ, Curfs-Breuker I, Klaassen CH, Meis JF.</emphasis> 2012. Species-specific antifungal susceptibility patterns of <citetitle><emphasis>Scedosporium</emphasis></citetitle> and <citetitle><emphasis>Pseudallescheria</emphasis></citetitle> species. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">56:</emphasis>2635–2642.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0077" role="bibliographyEntry">
            <para>77.<emphasis role="strong">Guinea J, Peláez T, Recio S, Torres-Narbona M, Bouza E.</emphasis> 2008. In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, <citetitle><emphasis>Candida</emphasis></citetitle>, <citetitle><emphasis>Aspergillus</emphasis></citetitle>, <citetitle><emphasis>Fusarium</emphasis></citetitle>, and <citetitle><emphasis>Scedosporium</emphasis></citetitle> species. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">52:</emphasis>1396–1400.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0078" role="bibliographyEntry">
            <para>78.<emphasis role="strong">Sanglard D, Coste AT.</emphasis> 2015. Activity of isavuconazole and other azoles against <citetitle><emphasis>Candida</emphasis></citetitle> clinical isolates and yeast model systems with known azole resistance mechanisms. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">60:</emphasis>229–238.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0079" role="bibliographyEntry">
            <para>79.<emphasis role="strong">Chowdhary A, Kathuria S, Randhawa HS, Gaur SN, Klaassen CH, Meis JF.</emphasis> 2012. Isolation of multiple-triazole-resistant <citetitle><emphasis>Aspergillus fumigatus</emphasis></citetitle> strains carrying the TR/L98H mutations in the cyp51A gene in India. <citetitle><emphasis>J Antimicrob Chemother</emphasis></citetitle> <emphasis role="strong">67:</emphasis>362–366.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0080" role="bibliographyEntry">
            <para>80.<emphasis role="strong">Viljoen J, Azie N, Schmitt-Hoffmann AH, Ghannoum M.</emphasis> 2015. A phase 2, randomized, double-blind, multicenter trial to evaluate the safety and efficacy of three dosing regimens of isavuconazole compared with fluconazole in patients with uncomplicated esophageal candidiasis. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">59:</emphasis>1671–1679.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0081" role="bibliographyEntry">
            <para>81.<emphasis role="strong">Desai AV, Kovanda LL, Hope WW, Andes D, Mouton JW, Kowalski DL, Townsend RW, Mujais S, Bonate PL.</emphasis> 2017. Exposure-response relationships for isavuconazole in patients with invasive aspergillosis and other filamentous fungi. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">61:</emphasis>e01034–17.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0082" role="bibliographyEntry">
            <para>82.<emphasis role="strong">Pfaller MA, Boyken L, Hollis RJ, Messer SA, Tendolkar S, Diekema DJ.</emphasis> 2005. In vitro susceptibilities of clinical isolates of <citetitle><emphasis>Candida</emphasis></citetitle> species, <citetitle><emphasis>Cryptococcus neoformans</emphasis></citetitle>, and <citetitle><emphasis>Aspergillus</emphasis></citetitle> species to itraconazole: global survey of 9,359 isolates tested by Clinical and Laboratory Standards Institute broth microdilution methods. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">43:</emphasis>3807–3810.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0083" role="bibliographyEntry">
            <para>83.<emphasis role="strong">Espinel-Ingroff A, Diekema DJ, Fothergill A, Johnson E, Pelaez T, Pfaller MA, Rinaldi MG, Canton E, Turnidge J.</emphasis> 2010. Wild-type MIC distributions and epidemiological cutoff values for the triazoles and six <citetitle><emphasis>Aspergillus</emphasis></citetitle> spp. for the CLSI broth microdilution method (M38-A2 document). <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">48:</emphasis>3251–3257.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0084" role="bibliographyEntry">
            <para>84.<emphasis role="strong">Masih A, Singh PK, Kathuria S, Agarwal K, Meis JF, Chowdhary A.</emphasis> 2016. Identification by molecular methods and matrix-assisted laser desorption ionization-time of flight mass spectrometry and antifungal susceptibility profiles of clinically significant rare <citetitle><emphasis>Aspergillus</emphasis></citetitle> species in a referral chest hospital in Delhi, India. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">54:</emphasis>2354–2364.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0085" role="bibliographyEntry">
            <anchor id="ch0155s0033s0002a0005"/>
            <para>85.<emphasis role="strong">Lockhart SR, Iqbal N, Cleveland AA, Farley MM, Harrison LH, Bolden CB, Baughman W, Stein B, Hollick R, Park BJ, Chiller T.</emphasis> 2012. Species identification and antifungal susceptibility testing of <citetitle><emphasis>Candida</emphasis></citetitle> bloodstream isolates from population-based surveillance studies in two U.S. cities from 2008 to 2011. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">50:</emphasis>3435–3442.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0086" role="bibliographyEntry">
            <para>86.<emphasis role="strong">Pfaller MA, Espinel-Ingroff A, Canton E, Castanheira M, Cuenca-Estrella M, Diekema DJ, Fothergill A, Fuller J, Ghannoum M, Jones RN, Lockhart SR, Martin-Mazuelos E, Melhem MS, Ostrosky-Zeichner L, Pappas P, Pelaez T, Peman J, Rex J, Szeszs MW.</emphasis> 2012. Wild-type MIC distributions and epidemiological cutoff values for amphotericin B, flucytosine, and itraconazole and <citetitle><emphasis>Candida</emphasis></citetitle> spp. as determined by CLSI broth microdilution. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">50:</emphasis>2040–2046.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0087" role="bibliographyEntry">
            <para>87.<emphasis role="strong">Li RK, Ciblak MA, Nordoff N, Pasarell L, Warnock DW, McGinnis MR.</emphasis> 2000. In vitro activities of voriconazole, itraconazole, and amphotericin B against <citetitle><emphasis>Blastomyces dermatitidis</emphasis></citetitle>, <citetitle><emphasis>Coccidioides immitis</emphasis></citetitle>, and <citetitle><emphasis>Histoplasma capsulatum. Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">44:</emphasis>1734–1736.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0088" role="bibliographyEntry">
            <para>88.<emphasis role="strong">Almyroudis NG, Sutton DA, Fothergill AW, Rinaldi MG, Kusne S.</emphasis> 2007. In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">51:</emphasis>2587–2590.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0089" role="bibliographyEntry">
            <para>89.<emphasis role="strong">Howard SJ, Cerar D, Anderson MJ, Albarrag A, Fisher MC, Pasqualotto AC, Laverdiere M, Arendrup MC, Perlin DS, Denning DW.</emphasis> 2009. Frequency and evolution of azole resistance in <citetitle><emphasis>Aspergillus fumigatus</emphasis></citetitle> associated with treatment failure. <citetitle><emphasis>Emerg Infect Dis</emphasis></citetitle> <emphasis role="strong">15:</emphasis>1068–1076.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0090" role="bibliographyEntry">
            <para>90.<emphasis role="strong">Burgel PR, Baixench MT, Amsellem M, Audureau E, Chapron J, Kanaan R, Honoré I, Dupouy-Camet J, Dusser D, Klaassen CH, Meis JF, Hubert D, Paugam A.</emphasis> 2012. High prevalence of azole-resistant <citetitle><emphasis>Aspergillus fumigatus</emphasis></citetitle> in adults with cystic fibrosis exposed to itraconazole. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">56:</emphasis>869–874.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0091" role="bibliographyEntry">
            <para>91.<emphasis role="strong">Mellado E, Garcia-Effron G, Alcázar-Fuoli L, Melchers WJ, Verweij PE, Cuenca-Estrella M, Rodríguez-Tudela JL.</emphasis> 2007. A new <citetitle><emphasis>Aspergillus fumigatus</emphasis></citetitle> resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of <citetitle><emphasis>cyp51A</emphasis></citetitle> alterations. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">51:</emphasis>1897–1904.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0092" role="bibliographyEntry">
            <para>92.<emphasis role="strong">Meis JF, Chowdhary A, Rhodes JL, Fisher MC, Verweij PE.</emphasis> 2016. Clinical implications of globally emerging azole resistance in <citetitle><emphasis>Aspergillus fumigatus. Philos Trans R Soc Lond B Biol Sci</emphasis></citetitle> <emphasis role="strong">371:</emphasis>20150460.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0093" role="bibliographyEntry">
            <para>93.<emphasis role="strong">Chapman SW, Dismukes WE, Proia LA, Bradsher RW, Pappas PG, Threlkeld MG, Kauffman CA, Infectious Diseases Society of America.</emphasis> 2008. Clinical practice guidelines for the management of blastomycosis: 2008 update by the Infectious Diseases Society of America. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">46:</emphasis>1801–1812.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0094" role="bibliographyEntry">
            <para>94.<emphasis role="strong">Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Segal BH, Steinbach WJ, Stevens DA, van Burik JA, Wingard JR, Patterson TF, Infectious Diseases Society of America.</emphasis> 2008. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">46:</emphasis>327–360.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0095" role="bibliographyEntry">
            <para>95.<emphasis role="strong">Thompson GR III, Lewis P, Mudge S, Patterson TF, Burnett BP.</emphasis> 2020. Open-label crossover oral bioequivalence pharmacokinetics comparison for a 3-day loading dose regimen and 15-day steady-state administration of SUBA-itraconazole and conventional itraconazole capsules in healthy adults. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">64:</emphasis>e00400–20.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0096" role="bibliographyEntry">
            <para>96.<emphasis role="strong">Hava DL, Tan L, Johnson P, Curran AK, Perry J, Kramer S, Kane K, Bedwell P, Layton G, Swann C, Henderson D, Khan N, Connor L, McKenzie L, Singh D, Roach J.</emphasis> 2020. A phase 1/1b study of PUR1900, an inhaled formulation of itraconazole, in healthy volunteers and asthmatics to study safety, tolerability and pharmacokinetics. <citetitle><emphasis>Br J Clin Pharmacol</emphasis></citetitle> <emphasis role="strong">86:</emphasis>723–733.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0097" role="bibliographyEntry">
            <para>97.<emphasis role="strong">Gupta AK, Lyons DC.</emphasis> 2015. The rise and fall of oral ketoconazole. <citetitle><emphasis>J Cutan Med Surg</emphasis></citetitle> <emphasis role="strong">19:</emphasis>352–357.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0098" role="bibliographyEntry">
            <para>98.<emphasis role="strong">Shadomy S, White SC, Yu HP, Dismukes WE.</emphasis> 1985. Treatment of systemic mycoses with ketoconazole: in vitro susceptibilities of clinical isolates of systemic and pathogenic fungi to ketoconazole. <citetitle><emphasis>J Infect Dis</emphasis></citetitle> <emphasis role="strong">152:</emphasis>1249–1256.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0099" role="bibliographyEntry">
            <para>99.<emphasis role="strong">Baddley JW, Marr KA, Andes DR, Walsh TJ, Kauffman CA, Kontoyiannis DP, Ito JI, Balajee SA, Pappas PG, Moser SA.</emphasis> 2009. Patterns of susceptibility of <citetitle><emphasis>Aspergillus</emphasis></citetitle> isolates recovered from patients enrolled in the Transplant-Associated Infection Surveillance Network. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">47:</emphasis>3271–3275.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0100" role="bibliographyEntry">
            <para>100.<emphasis role="strong">Espinel-Ingroff A, Pfaller MA, Bustamante B, Canton E, Fothergill A, Fuller J, Gonzalez GM, Lass-Flörl C, Lockhart SR, Martin-Mazuelos E, Meis JF, Melhem MS, Ostrosky-Zeichner L, Pelaez T, Szeszs MW, St-Germain G, Bonfietti LX, Guarro J, Turnidge J.</emphasis> 2014. Multilaboratory study of epidemiological cutoff values for detection of resistance in eight <citetitle><emphasis>Candida</emphasis></citetitle> species to fluconazole, posaconazole, and voriconazole. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">58:</emphasis>2006–2012.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0101" role="bibliographyEntry">
            <para>101.<emphasis role="strong">Paphitou NI, Ostrosky-Zeichner L, Paetznick VL, Rodriguez JR, Chen E, Rex JH.</emphasis> 2002. In vitro antifungal susceptibilities of <citetitle><emphasis>Trichosporon</emphasis></citetitle> species. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">46:</emphasis>1144–1146.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0102" role="bibliographyEntry">
            <para>102.<emphasis role="strong">Pfaller MA, Castanheira M, Diekema DJ, Messer SA, Jones RN.</emphasis> 2011. Wild-type MIC distributions and epidemiologic cutoff values for fluconazole, posaconazole, and voriconazole when testing <citetitle><emphasis>Cryptococcus neoformans</emphasis></citetitle> as determined by the CLSI broth microdilution method. <citetitle><emphasis>Diagn Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">71:</emphasis>252–259.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0103" role="bibliographyEntry">
            <para>103.<emphasis role="strong">Espinel-Ingroff A, Colombo AL, Cordoba S, Dufresne PJ, Fuller J, Ghannoum M, Gonzalez GM, Guarro J, Kidd SE, Meis JF, Melhem TM, Pelaez T, Pfaller MA, Szeszs MW, Takahaschi JP, Tortorano AM, Wiederhold NP, Turnidge J.</emphasis> 2015. International evaluation of MIC distributions and epidemiological cutoff value (ECV) definitions for <citetitle><emphasis>Fusarium</emphasis></citetitle> species identified by molecular methods for the CLSI broth microdilution method. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">60:</emphasis>1079–1084.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0104" role="bibliographyEntry">
            <para>104.<emphasis role="strong">Greenberg RN, Mullane K, van Burik JA, Raad I, Abzug MJ, Anstead G, Herbrecht R, Langston A, Marr KA, Schiller G, Schuster M, Wingard JR, Gonzalez CE, Revankar SG, Corcoran G, Kryscio RJ, Hare R.</emphasis> 2006. Posaconazole as salvage therapy for zygomycosis. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">50:</emphasis>126–133.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0105" role="bibliographyEntry">
            <para>105.<emphasis role="strong">Espinel-Ingroff A, Chakrabarti A, Chowdhary A, Cordoba S, Dannaoui E, Dufresne P, Fothergill A, Ghannoum M, Gonzalez GM, Guarro J, Kidd S, Lass-Flörl C, Meis JF, Pelaez T, Tortorano AM, Turnidge J.</emphasis> 2015. Multicenter evaluation of MIC distributions for epidemiologic cutoff value definition to detect amphotericin B, posaconazole, and itraconazole resistance among the most clinically relevant species of Mucorales. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">59:</emphasis>1745–1750.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0106" role="bibliographyEntry">
            <para>106.<emphasis role="strong">Vehreschild JJ, Birtel A, Vehreschild MJ, Liss B, Farowski F, Kochanek M, Sieniawski M, Steinbach A, Wahlers K, Fätkenheuer G, Cornely OA.</emphasis> 2013. Mucormycosis treated with posaconazole: review of 96 case reports. <citetitle><emphasis>Crit Rev Microbiol</emphasis></citetitle> <emphasis role="strong">39:</emphasis>310–324.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0107" role="bibliographyEntry">
            <para>107.<emphasis role="strong">van der Linden JW, Camps SM, Kampinga GA, Arends JP, Debets-Ossenkopp YJ, Haas PJ, Rijnders BJ, Kuijper EJ, van Tiel FH, Varga J, Karawajczyk A, Zoll J, Melchers WJ, Verweij PE.</emphasis> 2013. Aspergillosis due to voriconazole highly resistant <citetitle><emphasis>Aspergillus fumigatus</emphasis></citetitle> and recovery of genetically related resistant isolates from domiciles. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">57:</emphasis>513–520.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0108" role="bibliographyEntry">
            <para>108.<emphasis role="strong">Bueid A, Howard SJ, Moore CB, Richardson MD, Harrison E, Bowyer P, Denning DW.</emphasis> 2010. Azole antifungal resistance in <citetitle><emphasis>Aspergillus fumigatus</emphasis></citetitle>: 2008 and 2009. <citetitle><emphasis>J Antimicrob Chemother</emphasis></citetitle> <emphasis role="strong">65:</emphasis>2116–2118.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0109" role="bibliographyEntry">
            <para>109.<emphasis role="strong">Restrepo A, Tobón A, Clark B, Graham DR, Corcoran G, Bradsher RW, Goldman M, Pankey G, Moore T, Negroni R, Graybill JR.</emphasis> 2007. Salvage treatment of histoplasmosis with posaconazole. <citetitle><emphasis>J Infect</emphasis></citetitle> <emphasis role="strong">54:</emphasis>319–327.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0110" role="bibliographyEntry">
            <para>110.<emphasis role="strong">Kim MM, Vikram HR, Kusne S, Seville MT, Blair JE.</emphasis> 2011. Treatment of refractory coccidioidomycosis with voriconazole or posaconazole. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">53:</emphasis>1060–1066.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0111" role="bibliographyEntry">
            <anchor id="ch0155s0033s0002a0006"/>
            <para>111.<emphasis role="strong">van Burik JA, Hare RS, Solomon HF, Corrado ML, Kontoyiannis DP.</emphasis> 2006. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">42:</emphasis>e61–e65.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0112" role="bibliographyEntry">
            <para>112.<emphasis role="strong">Raad II, Graybill JR, Bustamante AB, Cornely OA, Gaona-Flores V, Afif C, Graham DR, Greenberg RN, Hadley S, Langston A, Negroni R, Perfect JR, Pitisuttithum P, Restrepo A, Schiller G, Pedicone L, Ullmann AJ.</emphasis> 2006. Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">42:</emphasis>1726–1734.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0113" role="bibliographyEntry">
            <para>113.<emphasis role="strong">Verweij PE, Chowdhary A, Melchers WJ, Meis JF.</emphasis> 2016. Azole resistance in <citetitle><emphasis>Aspergillus fumigatus</emphasis></citetitle>: can we retain the clinical use of mold-active antifungal azoles? <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">62:</emphasis>362–368.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0114" role="bibliographyEntry">
            <para>114.<emphasis role="strong">Malani AN, Kerr LE, Kauffman CA.</emphasis> 2015. Voriconazole: how to use this antifungal agent and what to expect. <citetitle><emphasis>Semin Respir Crit Care Med</emphasis></citetitle> <emphasis role="strong">36:</emphasis>786–795.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0115" role="bibliographyEntry">
            <para>115.<emphasis role="strong">Park S, Kelly R, Kahn JN, Robles J, Hsu MJ, Register E, Li W, Vyas V, Fan H, Abruzzo G, Flattery A, Gill C, Chrebet G, Parent SA, Kurtz M, Teppler H, Douglas CM, Perlin DS.</emphasis> 2005. Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical <citetitle><emphasis>Candida</emphasis></citetitle> sp. isolates. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">49:</emphasis>3264–3273.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0116" role="bibliographyEntry">
            <para>116.<emphasis role="strong">Sucher AJ, Chahine EB, Balcer HE.</emphasis> 2009. Echinocandins: the newest class of antifungals. <citetitle><emphasis>Ann Pharmacother</emphasis></citetitle> <emphasis role="strong">43:</emphasis>1647–1657.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0117" role="bibliographyEntry">
            <para>117.<emphasis role="strong">Pfaller MA, Espinel-Ingroff A, Bustamante B, Canton E, Diekema DJ, Fothergill A, Fuller J, Gonzalez GM, Guarro J, Lass-Flörl C, Lockhart SR, Martin-Mazuelos E, Meis JF, Ostrosky-Zeichner L, Pelaez T, St-Germain G, Turnidge J.</emphasis> 2014. Multicenter study of anidulafungin and micafungin MIC distributions and epidemiological cutoff values for eight <citetitle><emphasis>Candida</emphasis></citetitle> species and the CLSI M27-A3 broth microdilution method. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">58:</emphasis>916–922.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0118" role="bibliographyEntry">
            <para>118.<emphasis role="strong">Pfaller MA, Castanheira M, Lockhart SR, Ahlquist AM, Messer SA, Jones RN.</emphasis> 2012. Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of <citetitle><emphasis>Candida glabrata. J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">50:</emphasis>1199–1203.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0119" role="bibliographyEntry">
            <para>119.<emphasis role="strong">Lockhart SR, Pham CD, Kuykendall RJ, Bolden CB, Cleveland AA.</emphasis> 2015. <citetitle><emphasis>Candida lusitaniae</emphasis></citetitle> MICs to the echinocandins are elevated but FKS-mediated resistance is rare. <citetitle><emphasis>Diagn Microbiol Infect Dis</emphasis></citetitle> 10.1016/j.diagmicrobio.2015.08.012.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0120" role="bibliographyEntry">
            <para>120.<emphasis role="strong">Lockhart SR, Zimbeck AJ, Baddley JW, Marr KA, Andes DR, Walsh TJ, Kauffman CA, Kontoyiannis DP, Ito JI, Pappas PG, Chiller T.</emphasis> 2011. In vitro echinocandin susceptibility of <citetitle><emphasis>Aspergillus</emphasis></citetitle> isolates from patients enrolled in the Transplant-Associated Infection Surveillance Network. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">55:</emphasis>3944–3946.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0121" role="bibliographyEntry">
            <para>121.<emphasis role="strong">Pfaller MA, Boyken L, Hollis RJ, Kroeger J, Messer SA, Tendolkar S, Diekema DJ.</emphasis> 2010. Wild-type minimum effective concentration distributions and epidemiologic cutoff values for caspofungin and <citetitle><emphasis>Aspergillus</emphasis></citetitle> spp. as determined by Clinical and Laboratory Standards Institute broth microdilution methods. <citetitle><emphasis>Diagn Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">67:</emphasis>56–60.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0122" role="bibliographyEntry">
            <para>122.<emphasis role="strong">Espinel-Ingroff A.</emphasis> 2003. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature. <citetitle><emphasis>Rev Iberoam Micol</emphasis></citetitle> <emphasis role="strong">20:</emphasis>121–136.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0123" role="bibliographyEntry">
            <para>123.<emphasis role="strong">Nakai T, Uno J, Ikeda F, Tawara S, Nishimura K, Miyaji M.</emphasis> 2003. In vitro antifungal activity of micafungin (FK463) against dimorphic fungi: comparison of yeast-like and mycelial forms. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">47:</emphasis>1376–1381.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0124" role="bibliographyEntry">
            <para>124.<emphasis role="strong">Alexander BD, Johnson MD, Pfeiffer CD, Jiménez-Ortigosa C, Catania J, Booker R, Castanheira M, Messer SA, Perlin DS, Pfaller MA.</emphasis> 2013. Increasing echinocandin resistance in <citetitle><emphasis>Candida glabrata</emphasis></citetitle>: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">56:</emphasis>1724–1732.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0125" role="bibliographyEntry">
            <para>125.<emphasis role="strong">Shields RK, Nguyen MH, Press EG, Clancy CJ.</emphasis> 2014. Abdominal candidiasis is a hidden reservoir of echinocandin resistance. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">58:</emphasis>7601–7605.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0126" role="bibliographyEntry">
            <para>126.<emphasis role="strong">Perlin DS.</emphasis> 2007. Resistance to echinocandin-class antifungal drugs. <citetitle><emphasis>Drug Resist Updat</emphasis></citetitle> <emphasis role="strong">10:</emphasis>121–130.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0127" role="bibliographyEntry">
            <para>127.<emphasis role="strong">Pham CD, Iqbal N, Bolden CB, Kuykendall RJ, Harrison LH, Farley MM, Schaffner W, Beldavs ZG, Chiller TM, Park BJ, Cleveland AA, Lockhart SR.</emphasis> 2014. Role of FKS mutations in <citetitle><emphasis>Candida glabrata</emphasis></citetitle>: MIC values, echinocandin resistance, and multidrug resistance. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">58:</emphasis>4690–4696.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0128" role="bibliographyEntry">
            <para>128.<emphasis role="strong">Song JC, Stevens DA.</emphasis> 2016. Caspofungin: pharmacodynamics, pharmacokinetics, clinical uses and treatment outcomes. <citetitle><emphasis>Crit Rev Microbiol</emphasis></citetitle> <emphasis role="strong">42:</emphasis>813–846.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0129" role="bibliographyEntry">
            <para>129.<emphasis role="strong">Muilwijk EW, Lempers VJ, Burger DM, Warris A, Pickkers P, Aarnoutse RE, Brüggemann RJ.</emphasis> 2015. Impact of special patient populations on the pharmacokinetics of echinocandins. <citetitle><emphasis>Expert Rev Anti Infect Ther</emphasis></citetitle> <emphasis role="strong">13:</emphasis>799–815.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0130" role="bibliographyEntry">
            <para>130.<emphasis role="strong">Damle BD, Dowell JA, Walsky RL, Weber GL, Stogniew M, Inskeep PB.</emphasis> 2009. In vitro and in vivo studies to characterize the clearance mechanism and potential cytochrome P450 interactions of anidulafungin. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">53:</emphasis>1149–1156.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0131" role="bibliographyEntry">
            <para>131.<emphasis role="strong">Wagner C, Graninger W, Presterl E, Joukhadar C.</emphasis> 2006. The echinocandins: comparison of their pharmacokinetics, pharmacodynamics and clinical applications. <citetitle><emphasis>Pharmacology</emphasis></citetitle> <emphasis role="strong">78:</emphasis>161–177.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0132" role="bibliographyEntry">
            <para>132.<emphasis role="strong">Stone JA, Holland SD, Wickersham PJ, Sterrett A, Schwartz M, Bonfiglio C, Hesney M, Winchell GA, Deutsch PJ, Greenberg H, Hunt TL, Waldman SA.</emphasis> 2002. Single- and multiple-dose pharmacokinetics of caspofungin in healthy men. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">46:</emphasis>739–745.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0133" role="bibliographyEntry">
            <para>133.<emphasis role="strong">Hebert MF, Smith HE, Marbury TC, Swan SK, Smith WB, Townsend RW, Buell D, Keirns J, Bekersky I.</emphasis> 2005. Pharmacokinetics of micafungin in healthy volunteers, volunteers with moderate liver disease, and volunteers with renal dysfunction. <citetitle><emphasis>J Clin Pharmacol</emphasis></citetitle> <emphasis role="strong">45:</emphasis>1145–1152.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0134" role="bibliographyEntry">
            <para>134.<emphasis role="strong">Autmizguine J, Guptill JT, Cohen-Wolkowiez M, Benjamin DK Jr, Capparelli EV.</emphasis> 2014. Pharmacokinetics and pharmacodynamics of antifungals in children: clinical implications. <citetitle><emphasis>Drugs</emphasis></citetitle> <emphasis role="strong">74:</emphasis>891–909.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0135" role="bibliographyEntry">
            <para>135.<emphasis role="strong">Andes D, Diekema DJ, Pfaller MA, Bohrmuller J, Marchillo K, Lepak A.</emphasis> 2010. In vivo comparison of the pharmacodynamic targets for echinocandin drugs against <citetitle><emphasis>Candida</emphasis></citetitle> species. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">54:</emphasis>2497–2506.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0136" role="bibliographyEntry">
            <para>136.<emphasis role="strong">Goodwin ML, Drew RH.</emphasis> 2008. Antifungal serum concentration monitoring: an update. <citetitle><emphasis>J Antimicrob Chemother</emphasis></citetitle> <emphasis role="strong">61:</emphasis>17–25.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0137" role="bibliographyEntry">
            <para>137.<emphasis role="strong">Baginski M, Czub J.</emphasis> 2009. Amphotericin B and its new derivatives: mode of action. <citetitle><emphasis>Curr Drug Metab</emphasis></citetitle> <emphasis role="strong">10:</emphasis>459–469.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0138" role="bibliographyEntry">
            <para>138.<emphasis role="strong">Hamill RJ.</emphasis> 2013. Amphotericin B formulations: a comparative review of efficacy and toxicity. <citetitle><emphasis>Drugs</emphasis></citetitle> <emphasis role="strong">73:</emphasis>919–934.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0139" role="bibliographyEntry">
            <para>139.<emphasis role="strong">Zarif L, Graybill JR, Perlin D, Najvar L, Bocanegra R, Mannino RJ.</emphasis> 2000. Antifungal activity of amphotericin B cochleates against <citetitle><emphasis>Candida albicans</emphasis></citetitle> infection in a mouse model. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">44:</emphasis>1463–1469.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0140" role="bibliographyEntry">
            <para>140.<emphasis role="strong">Delmas G, Park S, Chen ZW, Tan F, Kashiwazaki R, Zarif L, Perlin DS.</emphasis> 2002. Efficacy of orally delivered cochleates containing amphotericin B in a murine model of aspergillosis. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">46:</emphasis>2704–2707.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0141" role="bibliographyEntry">
            <para>141.<emphasis role="strong">Jacobs SE, Zagaliotis P, Walsh TJ.</emphasis> 2021. Novel antifungal agents in clinical trials. <citetitle><emphasis>F1000 Res</emphasis></citetitle> <emphasis role="strong">10:</emphasis>507.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0142" role="bibliographyEntry">
            <para>142.<emphasis role="strong">Espinel-Ingroff A, Cuenca-Estrella M, Fothergill A, Fuller J, Ghannoum M, Johnson E, Pelaez T, Pfaller MA, Turnidge J.</emphasis> 2011. Wild-type MIC distributions and epidemiological cutoff values for amphotericin B and <citetitle><emphasis>Aspergillus</emphasis></citetitle> spp. for the CLSI broth microdilution method (M38-A2 document). <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">55:</emphasis>5150–5154.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0143" role="bibliographyEntry">
            <para>143.<emphasis role="strong">Kathuria S, Sharma C, Singh PK, Agarwal P, Agarwal K, Hagen F, Meis JF, Chowdhary A.</emphasis> 2015. Molecular epidemiology and in-vitro antifungal susceptibility of <citetitle><emphasis>Aspergillus terreus</emphasis></citetitle> species complex isolates in Delhi, India: evidence of genetic diversity by amplified fragment length polymorphism and microsatellite typing. <citetitle><emphasis>PLoS One</emphasis></citetitle> <emphasis role="strong">10:</emphasis>e0118997.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0144" role="bibliographyEntry">
            <para>144.<emphasis role="strong">Risslegger B, et al.</emphasis> 2017. A prospective international <citetitle><emphasis>Aspergillus terreus</emphasis></citetitle> survey: an EFISG, ISHAM and ECMM joint study. <citetitle><emphasis>Clin Microbiol Infect</emphasis></citetitle> <emphasis role="strong">23:</emphasis>776.e1–776.e5.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0145" role="bibliographyEntry">
            <anchor id="ch0155s0033s0002a0007"/>
            <para>145.<emphasis role="strong">Alcazar-Fuoli L, Mellado E, Alastruey-Izquierdo A, Cuenca-Estrella M, Rodriguez-Tudela JL.</emphasis> 2008. <citetitle><emphasis>Aspergillus</emphasis></citetitle> section <citetitle><emphasis>Fumigati</emphasis></citetitle>: antifungal susceptibility patterns and sequence-based identification. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">52:</emphasis>1244–1251.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0146" role="bibliographyEntry">
            <para>146.<emphasis role="strong">Cuenca-Estrella M, Gomez-Lopez A, Mellado E, Buitrago MJ, Monzon A, Rodriguez-Tudela JL.</emphasis> 2006. Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">50:</emphasis>917–921.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0147" role="bibliographyEntry">
            <para>147.<emphasis role="strong">Castanheira M, Duncanson FP, Diekema DJ, Guarro J, Jones RN, Pfaller MA.</emphasis> 2012. Activities of E1210 and comparator agents tested by CLSI and EUCAST broth microdilution methods against <citetitle><emphasis>Fusarium</emphasis></citetitle> and <citetitle><emphasis>Scedosporium</emphasis></citetitle> species identified using molecular methods. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">56:</emphasis>352–357.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0148" role="bibliographyEntry">
            <para>148.<emphasis role="strong">Ellis D.</emphasis> 2002. Amphotericin B: spectrum and resistance. <citetitle><emphasis>J Antimicrob Chemother</emphasis></citetitle> <emphasis role="strong">49</emphasis>(Suppl 1)<emphasis role="strong">:</emphasis>7–10.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0149" role="bibliographyEntry">
            <para>149.<emphasis role="strong">Kathuria S, Singh PK, Sharma C, Prakash A, Masih A, Kumar A, Meis JF, Chowdhary A.</emphasis> 2015. Multidrug-resistant <citetitle><emphasis>Candida auris</emphasis></citetitle> misidentified as <citetitle><emphasis>Candida haemulonii</emphasis></citetitle>: characterization by matrix-assisted laser desorption ionization-time of flight mass spectrometry and DNA sequencing and its antifungal susceptibility profile variability by Vitek 2, CLSI broth microdilution, and Etest method. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">53:</emphasis>1823–1830.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0150" role="bibliographyEntry">
            <para>150.<emphasis role="strong">Stone NR, Bicanic T, Salim R, Hope W.</emphasis> 2016. Liposomal amphotericin B (AmBisome®): a review of the pharmacokinetics, pharmacodynamics, clinical experience and future directions. <citetitle><emphasis>Drugs</emphasis></citetitle> <emphasis role="strong">76:</emphasis>485–500.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0151" role="bibliographyEntry">
            <para>151.<emphasis role="strong">Vogelsinger H, Weiler S, Djanani A, Kountchev J, Bellmann-Weiler R, Wiedermann CJ, Bellmann R.</emphasis> 2006. Amphotericin B tissue distribution in autopsy material after treatment with liposomal amphotericin B and amphotericin B colloidal dispersion. <citetitle><emphasis>J Antimicrob Chemother</emphasis></citetitle> <emphasis role="strong">57:</emphasis>1153–1160.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0152" role="bibliographyEntry">
            <para>152.<emphasis role="strong">Steimbach LM, Tonin FS, Virtuoso S, Borba HH, Sanches AC, Wiens A, Fernandez-Llimós F, Pontarolo R.</emphasis> 2017. Efficacy and safety of amphotericin B lipid-based formulations—a systematic review and meta-analysis. <citetitle><emphasis>Mycoses</emphasis></citetitle> <emphasis role="strong">60:</emphasis>146–154.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0153" role="bibliographyEntry">
            <para>153.<emphasis role="strong">Pfaller MA, Messer SA, Boyken L, Huynh H, Hollis RJ, Diekema DJ.</emphasis> 2002. In vitro activities of 5-fluorocytosine against 8,803 clinical isolates of <citetitle><emphasis>Candida</emphasis></citetitle> spp.: global assessment of primary resistance using National Committee for Clinical Laboratory Standards susceptibility testing methods. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">46:</emphasis>3518–3521.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0154" role="bibliographyEntry">
            <para>154.<emphasis role="strong">Vermes A, Guchelaar HJ, Dankert J.</emphasis> 2000. Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. <citetitle><emphasis>J Antimicrob Chemother</emphasis></citetitle> <emphasis role="strong">46:</emphasis>171–179.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0155" role="bibliographyEntry">
            <para>155.<emphasis role="strong">Gupta AK, Tu LQ.</emphasis> 2006. Therapies for onychomycosis: a review. <citetitle><emphasis>Dermatol Clin</emphasis></citetitle> <emphasis role="strong">24:</emphasis>375–379.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0156" role="bibliographyEntry">
            <para>156.<emphasis role="strong">Shaw KJ, Ibrahim AS.</emphasis> 2020. Fosmanogepix: a review of the first-in-class broad spectrum agent for the treatment of invasive fungal infections. <citetitle><emphasis>J Fungi (Basel)</emphasis></citetitle> <emphasis role="strong">6:</emphasis>239.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0157" role="bibliographyEntry">
            <para>157.<emphasis role="strong">Pfaller MA, Huband MD, Flamm RK, Bien PA, Castanheira M.</emphasis> 2021. Antimicrobial activity of manogepix, a first-in-class antifungal, and comparator agents tested against contemporary invasive fungal isolates from an international surveillance programme (2018-2019). <citetitle><emphasis>J Glob Antimicrob Resist</emphasis></citetitle> <emphasis role="strong">26:</emphasis>117–127.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0158" role="bibliographyEntry">
            <para>158.<emphasis role="strong">Hata K, Horii T, Miyazaki M, Watanabe NA, Okubo M, Sonoda J, Nakamoto K, Tanaka K, Shirotori S, Murai N, Inoue S, Matsukura M, Abe S, Yoshimatsu K, Asada M.</emphasis> 2011. Efficacy of oral E1210, a new broad-spectrum antifungal with a novel mechanism of action, in murine models of candidiasis, aspergillosis, and fusariosis. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">55:</emphasis>4543–4551.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0159" role="bibliographyEntry">
            <para>159.<emphasis role="strong">Pfaller MA, Duncanson F, Messer SA, Moet GJ, Jones RN, Castanheira M.</emphasis> 2011. In vitro activity of a novel broad-spectrum antifungal, E1210, tested against <citetitle><emphasis>Aspergillus</emphasis></citetitle> spp. determined by CLSI and EUCAST broth microdilution methods. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">55:</emphasis>5155–5158.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0160" role="bibliographyEntry">
            <para>160.<emphasis role="strong">Pfaller MA, Hata K, Jones RN, Messer SA, Moet GJ, Castanheira M.</emphasis> 2011. In vitro activity of a novel broad-spectrum antifungal, E1210, tested against <citetitle><emphasis>Candida</emphasis></citetitle> spp. as determined by CLSI broth microdilution method. <citetitle><emphasis>Diagn Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">71:</emphasis>167–170.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0161" role="bibliographyEntry">
            <para>161.<emphasis role="strong">Hoenigl M, Sprute R, Egger M, Arastehfar A, Cornely OA, Krause R, Lass-Flörl C, Prattes J, Spec A, Thompson GR III, Wiederhold N, Jenks JD.</emphasis> 2021. The antifungal pipeline: fosmanogepix, ibrexafungerp, olorofim, opelconazole, and rezafungin. <citetitle><emphasis>Drugs</emphasis></citetitle> <emphasis role="strong">81:</emphasis>1703–1729.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0162" role="bibliographyEntry">
            <para>162.<emphasis role="strong">Walker SS, Xu Y, Triantafyllou I, Waldman MF, Mendrick C, Brown N, Mann P, Chau A, Patel R, Bauman N, Norris C, Antonacci B, Gurnani M, Cacciapuoti A, McNicholas PM, Wainhaus S, Herr RJ, Kuang R, Aslanian RG, Ting PC, Black TA.</emphasis> 2011. Discovery of a novel class of orally active antifungal beta-1,3-d-glucan synthase inhibitors. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">55:</emphasis>5099–5106.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0163" role="bibliographyEntry">
            <para>163.<emphasis role="strong">Jiménez-Ortigosa C, Paderu P, Motyl MR, Perlin DS.</emphasis> 2014. Enfumafungin derivative MK-3118 shows increased in vitro potency against clinical echinocandin-resistant <citetitle><emphasis>Candida</emphasis></citetitle> species and <citetitle><emphasis>Aspergillus</emphasis></citetitle> species isolates. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">58:</emphasis>1248–1251.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0164" role="bibliographyEntry">
            <para>164.<emphasis role="strong">Nunnally NS, Etienne KA, Angulo D, Lockhart SR, Berkow EL.</emphasis> 2019. In vitro activity of ibrexafungerp, a novel glucan synthase inhibitor against <citetitle><emphasis>Candida glabrata</emphasis></citetitle> isolates with FKS mutations. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">63:</emphasis>e01692–19.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0165" role="bibliographyEntry">
            <para>165.<emphasis role="strong">Berkow EL, Angulo D, Lockhart SR.</emphasis> 2017. In vitro activity of a novel glucan synthase inhibitor, SCY-078, against clinical isolates of <citetitle><emphasis>Candida auris. Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">61:</emphasis>e00435–17.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0166" role="bibliographyEntry">
            <para>166.<emphasis role="strong">Pfaller MA, Messer SA, Motyl MR, Jones RN, Castanheira M.</emphasis> 2013. Activity of MK-3118, a new oral glucan synthase inhibitor, tested against Candida spp. by two international methods (CLSI and EUCAST). <citetitle><emphasis>J Antimicrob Chemother</emphasis></citetitle> <emphasis role="strong">68:</emphasis>858–863.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0167" role="bibliographyEntry">
            <para>167.<emphasis role="strong">Lamoth F, Alexander BD.</emphasis> 2015. Antifungal activities of SCY-078 (MK-3118) and standard antifungal agents against clinical non-<citetitle><emphasis>Aspergillus</emphasis></citetitle> mold isolates. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">59:</emphasis>4308–4311.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0168" role="bibliographyEntry">
            <para>168.<emphasis role="strong">Oliver JD, Sibley GEM, Beckmann N, Dobb KS, Slater MJ, McEntee L, du Pré S, Livermore J, Bromley MJ, Wiederhold NP, Hope WW, Kennedy AJ, Law D, Birch M.</emphasis> 2016. F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase. <citetitle><emphasis>Proc Natl Acad Sci USA</emphasis></citetitle> <emphasis role="strong">113:</emphasis>12809–12814.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0169" role="bibliographyEntry">
            <para>169.<emphasis role="strong">Hope WW, McEntee L, Livermore J, Whalley S, Johnson A, Farrington N, Kolamunnage-Dona R, Schwartz J, Kennedy A, Law D, Birch M, Rex JH.</emphasis> 2017. Pharmacodynamics of the orotomides against <citetitle><emphasis>Aspergillus fumigatus</emphasis></citetitle>: new opportunities for treatment of multidrug-resistant fungal disease. <citetitle><emphasis>MBio</emphasis></citetitle> <emphasis role="strong">8:</emphasis>e01157–17.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0170" role="bibliographyEntry">
            <para>170.<emphasis role="strong">Wiederhold NP, Law D, Birch M.</emphasis> 2017. Dihydroorotate dehydrogenase inhibitor F901318 has potent in vitro activity against Scedosporium species and Lomentospora prolificans. <citetitle><emphasis>J Antimicrob Chemother</emphasis></citetitle> <emphasis role="strong">72:</emphasis>1977–1980.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0171" role="bibliographyEntry">
            <para>171.<emphasis role="strong">Wiederhold NP.</emphasis> 2017. The antifungal arsenal: alternative drugs and future targets. <citetitle><emphasis>Int J Antimicrob Agents</emphasis></citetitle> 10.1016/j.ijantimicag.2017.09.002.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0172" role="bibliographyEntry">
            <para>172.<emphasis role="strong">Buil JBRA, et al.</emphasis> 2016. Activity of F901318 against azole-resistant and difficult-to-treat <citetitle><emphasis>Aspergillus</emphasis></citetitle> species. <citetitle><emphasis>Abstr 26th European Congress of Clinical Microbiology and Infectious Disease</emphasis></citetitle>, Amsterdam, The Netherlands.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0173" role="bibliographyEntry">
            <para>173.<emphasis role="strong">Ong V, Hough G, Schlosser M, Bartizal K, Balkovec JM, James KD, Krishnan BR.</emphasis> 2016. Preclinical evaluation of the stability, safety, and efficacy of CD101, a novel echinocandin. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">60:</emphasis>6872–6879.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0174" role="bibliographyEntry">
            <para>174.<emphasis role="strong">Ong V, James KD, Smith S, Krishnan BR.</emphasis> 2017. Pharmacokinetics of the novel echinocandin CD101 in multiple animal species. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">61:</emphasis>e01626–16.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0175" role="bibliographyEntry">
            <para>175.<emphasis role="strong">Pfaller MA, Messer SA, Rhomberg PR, Castanheira M.</emphasis> 2017. Activity of a long-acting echinocandin (CD101) and seven comparator antifungal agents tested against a global collection of contemporary invasive fungal isolates in the SENTRY 2014 Antifungal Surveillance Program. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">61:</emphasis>e02045–16.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0176" role="bibliographyEntry">
            <para>176.<emphasis role="strong">Zhao Y, Perez WB, Jiménez-Ortigosa C, Hough G, Locke JB, Ong V, Bartizal K, Perlin DS.</emphasis> 2016. CD101: a novel long-acting echinocandin. <citetitle><emphasis>Cell Microbiol</emphasis></citetitle> <emphasis role="strong">18:</emphasis>1308–1316.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0177" role="bibliographyEntry">
            <anchor id="ch0155s0033s0002a0008"/>
            <para>177.<emphasis role="strong">Hoekstra WJ, Garvey EP, Moore WR, Rafferty SW, Yates CM, Schotzinger RJ.</emphasis> 2014. Design and optimization of highly-selective fungal CYP51 inhibitors. <citetitle><emphasis>Bioorg Med Chem Lett</emphasis></citetitle> <emphasis role="strong">24:</emphasis>3455–3458.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0178" role="bibliographyEntry">
            <para>178.<emphasis role="strong">Break TJ, Desai JV, Natarajan M, Ferre EMN, Henderson C, Zelazny AM, Siebenlist U, Hoekstra WJ, Schotzinger RJ, Garvey EP, Lionakis MS.</emphasis> 2017. VT-1161 protects mice against oropharyngeal candidiasis caused by fluconazole-susceptible and -resistant <citetitle><emphasis>Candida albicans. J Antimicrob Chemother</emphasis></citetitle> 10.1093/jac/dkx352.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0179" role="bibliographyEntry">
            <para>179.<emphasis role="strong">Shubitz LF, Trinh HT, Galgiani JN, Lewis ML, Fothergill AW, Wiederhold NP, Barker BM, Lewis ER, Doyle AL, Hoekstra WJ, Schotzinger RJ, Garvey EP.</emphasis> 2015. Evaluation of VT-1161 for treatment of coccidioidomycosis in murine infection models. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">59:</emphasis>7249–7254.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0180" role="bibliographyEntry">
            <para>180.<emphasis role="strong">Warrilow AG, Hull CM, Parker JE, Garvey EP, Hoekstra WJ, Moore WR, Schotzinger RJ, Kelly DE, Kelly SL.</emphasis> 2014. The clinical candidate VT-1161 is a highly potent inhibitor of Candida albicans CYP51 but fails to bind the human enzyme. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">58:</emphasis>7121–7127.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0181" role="bibliographyEntry">
            <para>181.<emphasis role="strong">Garvey EP, Hoekstra WJ, Moore WR, Schotzinger RJ, Long L, Ghannoum MA.</emphasis> 2015. VT-1161 dosed once daily or once weekly exhibits potent efficacy in treatment of dermatophytosis in a guinea pig model. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">59:</emphasis>1992–1997.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0182" role="bibliographyEntry">
            <para>182.<emphasis role="strong">Wiederhold NP, et al.</emphasis> 2017. <citetitle><emphasis>The novel fungal Cyp51 inhibitor VT-1598 demonstrates potent in vitro activity against endemic fungi, Aspergillus, and Rhizopus.</emphasis></citetitle> Abstr ASM Microbe, New Orleans, LA.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0183" role="bibliographyEntry">
            <para>183.<emphasis role="strong">Wiederhold NP, Patterson H, Yates CM, Schotzinger RJ, Garvey EP.</emphasis> 2017. <citetitle><emphasis>The novel fungal Cyp51 inhibitor VT-1598 demonstrates potent in vitro activity against Candida and Cryptococcus species.</emphasis></citetitle> Abstr ASM Microbe, New Orleans, LA.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0184" role="bibliographyEntry">
            <para>184.<emphasis role="strong">Berkow EL, Peterson J, Garvey EP, Yates CM, Schotzinger RJ, Lockhart SR.</emphasis> 2017. In vitro <citetitle><emphasis>activity of a novel Cyp51 inhibitor VT-1598 against clinical isolates of Candida auris.</emphasis></citetitle> Abstr ASM Microbe, New Orleans, LA.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0185" role="bibliographyEntry">
            <para>185.<emphasis role="strong">Dietz AJ, Barnard JC, van Rossem K.</emphasis> 2014. A randomized, double-blind, multiple-dose, placebo-controlled, dose escalation study with a 3-cohort parallel group design to investigate the tolerability and pharmacokinetics of albaconazole in healthy subjects. <citetitle><emphasis>Clin Pharmacol Drug Dev</emphasis></citetitle> <emphasis role="strong">3:</emphasis>25–33.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0186" role="bibliographyEntry">
            <para>186.<emphasis role="strong">Sigurgeirsson B, van Rossem K, Malahias S, Raterink K.</emphasis> 2013. A phase II, randomized, double-blind, placebo-controlled, parallel group, dose-ranging study to investigate the efficacy and safety of 4 dose regimens of oral albaconazole in patients with distal subungual onychomycosis. <citetitle><emphasis>J Am Acad Dermatol</emphasis></citetitle> <emphasis role="strong">69:</emphasis>416–425.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0187" role="bibliographyEntry">
            <para>187.<emphasis role="strong">van Rossem K, Lowe JA.</emphasis> 2013. A Phase 1, randomized, open-label crossover study to evaluate the safety and pharmacokinetics of 400 mg albaconazole administered to healthy participants as a tablet formulation versus a capsule formulation. <citetitle><emphasis>Clin Pharmacol</emphasis></citetitle> <emphasis role="strong">5:</emphasis>23–31.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0188" role="bibliographyEntry">
            <para>188.<emphasis role="strong">Murray A, Cass L, Ito K, Pagani N, Armstrong-James D, Dalal P, Reed A, Strong P.</emphasis> 2020. PC945, a novel inhaled antifungal agent, for the treatment of respiratory fungal infections. <citetitle><emphasis>J Fungi (Basel)</emphasis></citetitle> <emphasis role="strong">6:</emphasis>373.</para>
          </listitem>
          <listitem id="ch0155s0033s0002li0189" role="bibliographyEntry">
            <para>189.<emphasis role="strong">Colley T, Alanio A, Kelly SL, Sehra G, Kizawa Y, Warrilow AGS, Parker JE, Kelly DE, Kimura G, Anderson-Dring L, Nakaoki T, Sunose M, Onions S, Crepin D, Lagasse F, Crittall M, Shannon J, Cooke M, Bretagne S, King-Underwood J, Murray J, Ito K, Strong P, Rapeport G.</emphasis> 2017. In vitro and in vivo antifungal profile of a novel and long-acting inhaled azole, PC945, on <citetitle><emphasis>Aspergillus fumigatus</emphasis></citetitle> infection. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">61:</emphasis>e02280–16.</para>
          </listitem>
        </itemizedlist>
      </sect2>
    </sect1>
  </chapter>
